1
|
Scott M, Watermeyer J, Wessels TM. "We are just not sure what that means or if it's relevant": Uncertainty when gathering family history information in South African prenatal genetic counseling consultations. Soc Sci Med 2024; 342:116555. [PMID: 38176214 DOI: 10.1016/j.socscimed.2023.116555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 12/19/2023] [Accepted: 12/22/2023] [Indexed: 01/06/2024]
Abstract
Uncertainty impacts the process of health communication. The management and tolerance of uncertainty during healthcare discussions have gained renewed focus due to the growing challenge of obtaining and delivering complex health information, and the offer of health services in diverse contexts. Prenatal genetic counseling (GC) provides education, support and testing options for patients and couples facing a genetic or congenital diagnosis or risk during pregnancy. Gathering detailed and accurate family history information is essential to determine a patient's genetic risk. In South Africa, contextual factors such as patient literacy, language diversity, limited written patient health records, and a lack of familiarity with GC services may increase the potential for misunderstandings during GC consultations. This study uses a qualitative sociolinguistic approach to analyse 9 video-recorded South African prenatal GC consultations to understand the impact of uncertainty on the process of gathering family history information. The findings reveal uncertainty is introduced in different ways during family history taking. This includes when patients have no knowledge about their family history; when they have some knowledge but the details are unclear; or when patients have knowledge but the details are confusing. Uncertainty can lead to interactional trouble in the form of knowledge asymmetries, interrogative questioning, reversals in epistemic authority, and the potential for mistrust. Suggestions are made for how genetic specialists can manage uncertainty in GC family history taking. These include recognizing contextual sources of uncertainty, understanding how patients may respond to uncertainty and being aware of personal responses to moments of discomfort. Specific communication training recommendations and video-based sociolinguistic methods to enhance reflection and communication practice are highlighted. These approaches may enhance the effectiveness of GC communication and strengthen patient-specialist relationships, especially in diverse settings.
Collapse
Affiliation(s)
- Megan Scott
- The Health Communication Research Unit (HCRU), School of Human & Community Development, Faculty of Humanities, University of the Witwatersrand, Johannesburg, South Africa.
| | - Jennifer Watermeyer
- The Health Communication Research Unit (HCRU), School of Human & Community Development, Faculty of Humanities, University of the Witwatersrand, Johannesburg, South Africa
| | - Tina-Marie Wessels
- Division of Human Genetics, Department of Pathology, Faculty of Health Science, University of Cape Town, Cape Town, South Africa
| |
Collapse
|
2
|
Kilbride M, Egleston BL, Chung WK, Olopade O, Maxwell KN, Shah P, Churpek JE, Fleisher L, Terry MB, Fetzer D, Gaieski JB, Bulafka J, Espinal A, Karpink K, Walser S, Singleton D, Palese M, Siljander I, Brandt A, Clark D, Koval C, Wynn J, Long JM, McKenna D, Powers J, Nielsen S, Domchek SM, Nathanson KL, Bradbury AR. Uptake of Genetic Research Results and Patient-Reported Outcomes With Return of Results Incorporating Web-Based Predisclosure Education. J Clin Oncol 2023; 41:4905-4915. [PMID: 37611220 PMCID: PMC10617912 DOI: 10.1200/jco.22.00516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 05/04/2023] [Accepted: 06/21/2023] [Indexed: 08/25/2023] Open
Abstract
PURPOSE We developed a web-based education intervention as an alternative to predisclosure education with a genetic counselor (GC) to reduce participant burden and provider costs with return of genetic research results. METHODS Women at three sites who participated in 11 gene discovery research studies were contacted to consider receiving cancer genetic research results. Participants could complete predisclosure education through web education or with a GC. Outcomes included uptake of research results, factors associated with uptake, and patient-reported outcomes. RESULTS Of 819 participants, 178 actively (21.7%) and 167 passively (20.4%) declined return of results; 474 (57.9%) were enrolled. Most (60.3%) received results although this was lower than the 70% uptake we hypothesized. Passive and active decliners were more likely to be Black, to have less education, and to have not received phone follow-up after the invitation letter. Most participants selected web education (88.5%) as an alternative to speaking with a GC, but some did not complete or receive results. Knowledge increased significantly from baseline to other time points with no significant differences between those who received web versus GC education. There were no significant increases in distress between web and GC education. CONCLUSION Interest in web-based predisclosure education for return of genetic research results was high although it did not increase uptake of results. We found no negative patient-reported outcomes with web education, suggesting that it is a viable alternative delivery model for reducing burdens and costs of returning genetic research results. Attention to attrition and lower uptake of results among Black participants and those with less formal education are important areas for future research.
Collapse
Affiliation(s)
- Madison Kilbride
- Department of Philosophy, University of Utah, Salt Lake City, UT
| | | | - Wendy K. Chung
- Department of Pediatrics and Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York City, NY
| | | | - Kara N. Maxwell
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Payal Shah
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | | | - Linda Fleisher
- Fox Chase Cancer Center, Temple University, Philadelphia, PA
| | - Mary Beth Terry
- Herbert Irving Comprehensive Cancer Center and the Mailman School of Public Health, Columbia University Irving Medical Center, New York City, NY
| | - Dominique Fetzer
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Jill Bennett Gaieski
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Jessica Bulafka
- Herbert Irving Comprehensive Cancer Center and the Mailman School of Public Health, Columbia University Irving Medical Center, New York City, NY
| | - Aileen Espinal
- Herbert Irving Comprehensive Cancer Center and the Mailman School of Public Health, Columbia University Irving Medical Center, New York City, NY
| | - Kelsey Karpink
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Sarah Walser
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Davone Singleton
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | | | | | - Amanda Brandt
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Dana Clark
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Carrie Koval
- Department of Pediatrics, Columbia University Irving Medical Center, New York City, NY
| | - Julia Wynn
- Department of Pediatrics, Columbia University, New York City, NY
| | - Jessica M. Long
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Danielle McKenna
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Jacquelyn Powers
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | | | - Susan M. Domchek
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
| | - Katherine L. Nathanson
- Division of Translational Medicine and Human Genetics, The University of Pennsylvania, Philadelphia, PA
| | - Angela R. Bradbury
- Division of Hematology-Oncology, Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA
- Department of Medical Ethics and Health Policy, The University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
3
|
Nakazawa A, Iwamoto M, Kurazume R, Nunoi M, Kobayashi M, Honda M. Augmented reality-based affective training for improving care communication skill and empathy. PLoS One 2023; 18:e0288175. [PMID: 37428739 DOI: 10.1371/journal.pone.0288175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2022] [Accepted: 06/21/2023] [Indexed: 07/12/2023] Open
Abstract
It is important for caregivers of people with dementia (PwD) to have good patient communication skills as it has been known to reduce the behavioral and psychological symptoms of dementia (BPSD) of PwD as well as caregiver burnout. However, acquiring such skills often requires one-on-one affective training, which can be costly. In this study, we propose affective training using augmented reality (AR) for supporting the acquisition of such skills. The system uses see-through AR glasses and a nursing training doll to train the user in both practical nursing skills and affective skills such as eye contact and patient communication. The experiment was conducted with 38 nursing students. The participants were assigned to either the Doll group, which only used a doll for training, or the AR group, which used both a doll and the AR system. The results showed that eye contact significantly increased and the face-to-face distance and angle decreased in the AR group, while the Doll group had no significant difference. In addition, the empathy score of the AR group significantly increased after the training. Upon analyzing the correlation between personality and changes of physical skills, we found a significant positive correlation between the improvement rate of eye contact and extraversion in the AR group. These results demonstrated that affective training using AR is effective for improving caregivers' physical skills and their empathy for their patients. We believe that this system will be beneficial not only for dementia caregivers but for anyone looking to improve their general communication skills.
Collapse
Affiliation(s)
- Atsushi Nakazawa
- Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan
| | - Miyuki Iwamoto
- Department of Advanced Fibro-Science, Kyoto Institute of Technology, Kyoto, Japan
| | - Ryo Kurazume
- Faculty of Information Science and Electrical Engineering, Kyushu University, Fukuoka, Japan
| | - Masato Nunoi
- School of Human Sciences, Sugiyama Jogakuen University, Nagoya, Aichi, Japan
| | - Masaki Kobayashi
- Division of geriatric medicine, Rochester Regional Health System, Rochester, NY, United States of America
| | - Miwako Honda
- Division of Geriatric Research, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
| |
Collapse
|
4
|
Kobayashi M, Katayama M, Hayashi T, Hashiyama T, Iyanagi T, Une S, Honda M. Effect of multimodal comprehensive communication skills training with video analysis by artificial intelligence for physicians on acute geriatric care: a mixed-methods study. BMJ Open 2023; 13:e065477. [PMID: 36868602 PMCID: PMC9990644 DOI: 10.1136/bmjopen-2022-065477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/05/2023] Open
Abstract
OBJECTIVES To quantitatively analyse by artificial intelligence (AI) the communication skills of physicians in an acute care hospital for geriatric care following a multimodal comprehensive care communication skills training programme and to qualitatively explore the educational benefits of this training programme. DESIGN A convergent mixed-methods study, including an intervention trial with a quasi-experimental design, was conducted to quantitatively analyse the communication skills of physicians. Qualitative data were collected via physicians' responses to an open-ended questionnaire administered after the training. SETTING An acute care hospital. PARTICIPANTS A total of 23 physicians. INTERVENTIONS In a 4-week multimodal comprehensive care communication skills training programme, including video lectures and bedside instruction, from May to October 2021, all the participants examined a simulated patient in the same scenario before and after their training. These examinations were video recorded by an eye-tracking camera and two fixed cameras. Then, the videos were analysed for communication skills by AI. MAIN OUTCOME MEASURES The primary outcomes were the physicians' eye contact, verbal expression, physical touch and multimodal communication skills with a simulated patient. The secondary outcomes were the physicians' empathy and burnout scores. RESULTS The proportion of the duration of the participants' single and multimodal types of communication significantly increased (p<0.001). The mean empathy scores and the personal accomplishment burnout scores also significantly increased after training. We developed a learning cycle model based on the six categories that changed after training from the physicians' perspective: multimodal comprehensive care communication skills training; increasing awareness of and sensitivity to changes to geriatric patients' condition; changes in clinical management; professionalism; team building and personal accomplishments. CONCLUSIONS Our study showed that multimodal comprehensive care communication skills training for physicians increased the proportions of time spent performing single and multimodal communication skills by video analysis through AI. TRIAL REGISTRATION NUMBER UMIN Clinical Trials Registry (UMIN000044288; https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050586).
Collapse
Affiliation(s)
- Masaki Kobayashi
- Department of Geriatric Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
- Division of Geriatric Medicine, Rochester Regional Health System, Rochester, New York, USA
| | - Mitsuya Katayama
- Department of General Internal Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
| | - Tomofumi Hayashi
- Department of General Internal Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
| | - Takuhiro Hashiyama
- Department of General Internal Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
| | - Toshinori Iyanagi
- Department of General Internal Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
| | - Saki Une
- Department of Geriatric Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
| | - Miwako Honda
- Department of Geriatric Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
- Department of General Internal Medicine, National Hospital Organization Tokyo Medical Centre, Meguro-ku, Japan
| |
Collapse
|
5
|
The Influence of Face Gaze by Physicians on Patient Trust: an Observational Study. J Gen Intern Med 2022; 37:1408-1414. [PMID: 34031854 PMCID: PMC9086012 DOI: 10.1007/s11606-021-06906-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 04/30/2021] [Indexed: 11/04/2022]
Abstract
BACKGROUND Physicians' gaze towards their patients may affect patients' trust in them. This is especially relevant considering recent developments, including the increasing use of Electronic Health Records, which affect physicians' gaze behavior. Moreover, socially anxious patients' trust in particular may be affected by the gaze of the physician. OBJECTIVE We aimed to evaluate if physicians' gaze towards the face of their patient influenced patient trust and to assess if this relation was stronger for socially anxious patients. We furthermore explored the relation between physicians' gaze and patients' perception of physician empathy and patients' distress. DESIGN This was an observational study using eye-tracking glasses and questionnaires. PARTICIPANTS One hundred patients and 16 residents, who had not met before, participated at an internal medicine out-patient clinic. MEASURES Physicians wore eye-tracking glasses during medical consultations to assess their gaze towards patients' faces. Questionnaires were used to assess patient outcomes. Multilevel analyses were conducted to assess the relation between physicians' relative face gaze time and trust, while correcting for patient background characteristics, and including social anxiety as a moderator. Analyses were then repeated with perceived empathy and distress as outcomes. RESULTS More face gaze towards patients was associated with lower trust, after correction for gender, age, education level, presence of caregivers, and social anxiety (β=-0.17, P=0.048). There was no moderation effect of social anxiety nor a relation between face gaze and perceived empathy or distress. CONCLUSIONS These results challenge the notion that more physician gaze is by definition beneficial for the physician-patient relationship. For example, the extent of conversation about emotional issues might explain our findings, where more emotional talk could be associated with more intense gazing and feelings of discomfort in the patient. To better understand the relation between physician gaze and patient outcomes, future studies should assess bidirectional face gaze during consultations.
Collapse
|
6
|
Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review. J Pers Med 2021; 11:jpm11090850. [PMID: 34575627 PMCID: PMC8467628 DOI: 10.3390/jpm11090850] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 08/23/2021] [Accepted: 08/25/2021] [Indexed: 01/01/2023] Open
Abstract
Background: Patient-reported outcomes (PROs) and PRO measures (PROMs) are real-world evidence that can help capture patient experiences and perspectives regarding a clinical intervention such as genetic testing. Objective: To identify and capture methods and qualitative PRO themes among studies reporting PROs following genetic testing for FH, breast and ovarian cancer syndrome, and Lynch syndrome. Methods: A systematic review was conducted via PubMed/MEDLINE, EMBASE, and Yale University’s TRIP Medical Databases on articles published by April 2021. Results: We identified 24 studies published between 1996 and 2021 representing 4279 participants that reported PROs following genetic testing for FH, breast and ovarian cancer syndrome, and Lynch syndrome. Studies collected and reported PROs from validated PROM instruments (n = 12; 50%), validated surveys (n = 7; 26%), and interviews (n = 10; 42%). PRO themes ranged across all collection methods (e.g., psychological, knowledge, coping and satisfaction, concern about stigma/discrimination, etc.). Conclusions: Important gaps identified include (1) most studies (n = 18; 75%) reported PROs following genetic testing for breast and ovarian cancer, and (2) populations reporting PROs overall were largely of White/Caucasian/Northern European/Anglo-Saxon descent. We offer recommendations and describe real-world implications for the field moving forward.
Collapse
|
7
|
Redlinger-Grosse K, MacFarlane IM, Cragun D, Zierhut H. A Delphi study to prioritize genetic counseling outcomes: What matters most. J Genet Couns 2020; 30:676-692. [PMID: 33179357 DOI: 10.1002/jgc4.1352] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Revised: 09/28/2020] [Accepted: 10/01/2020] [Indexed: 11/06/2022]
Abstract
Research on genetic counseling outcomes has examined a range of metrics many that differ in quality and extent of psychometric assessment and in some cases fail to encompass potential benefits of genetic counseling for patients. Although a variety of possible outcomes have been explored, selecting the most important or relevant outcomes and identifying well-validated measures remain challenging. An online, modified Delphi method was used to prioritize genetic counseling outcomes from the viewpoint of individuals from four stakeholder groups - clinical genetic counselors, outcome researchers, genetic counseling training directors, and genetic counseling consumers/advocates. A survey of 181 genetic counseling outcomes were rated based on perceived importance and then sorted and categorized using the Framework for Outcomes of Clinical Communication Services in Genetic Counseling (FOCUS-GC) framework. Three of the FOCUS-GC domains (Process, Patient Care Experience, and Patient Changes) were assessed as most important, while none of the most highly rated outcomes fell into the domains of Patient Health or Family Changes. The majority of outcomes deemed most important by stakeholder groups were within the process domain. When looking at the proportion of outcomes that overlapped with the consumer group, clinical genetic counselors had the highest degree of similarity with consumers when looking at the high relative importance band outcomes (61.1% overlap), followed by training directors (58.3%), and outcome researchers (41.7%). Variability in importance according to stakeholder groups was an important consideration and prioritizing outcomes was challenging given that the majority of outcomes were rated as important. Working to bridge the realities of clinical care and fundamental differences in the viewpoints and priorities of genetic counseling research directions is an area for future exploration.
Collapse
Affiliation(s)
| | | | - Deborah Cragun
- College of Public Health, University of South Florida, Tampa, FL, USA
| | - Heather Zierhut
- Department of Genetics, Cell Biology, and Development, Institute of Human Genetics, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
8
|
Jongerius C, Hessels RS, Romijn JA, Smets EMA, Hillen MA. The Measurement of Eye Contact in Human Interactions: A Scoping Review. JOURNAL OF NONVERBAL BEHAVIOR 2020. [DOI: 10.1007/s10919-020-00333-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
AbstractEye contact is a fundamental aspect of nonverbal communication and therefore important for understanding human interaction. Eye contact has been the subject of research in many disciplines, including communication sciences, social psychology, and psychiatry, and a variety of techniques have been used to measure it. The choice of measurement method has consequences for research outcomes and their interpretation. To ensure that research findings align with study aims and populations, it is essential that methodological choices are well substantiated. Therefore, to enhance the effective examination of eye contact, we performed a literature review of the methods used to study eye contact. We searched Medline, PsycINFO and Web of Science for empirical peer-reviewed articles published in English that described quantitative studies on human eye contact and included a methodological description. The identified studies (N = 109) used two approaches to assess eye contact: direct, i.e., assessing eye contact while it is occurring, and indirect, i.e., assessing eye contact retrospectively (e.g., from video recordings). Within these categories, eight specific techniques were distinguished. Variation was found regarding the reciprocity of eye contact between two individuals, the involvement of an assessor and the behavior of participants while being studied. Measures not involving the interactors in assessment of eye contact and have a higher spatial and temporal resolution, such as eye tracking, have gained popularity. Our results show wide methodological diversity regarding the measurement of eye contact. Although studies often define eye contact as gaze towards an exact location, this may not do justice to the subjective character of eye contact. The various methodologies have hardly ever been compared, limiting the ability to compare findings between studies. Future studies should take notice of the controversy surrounding eye contact measures.
Collapse
|
9
|
Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM. Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients. Clin Genet 2020; 97:601-609. [PMID: 32022897 PMCID: PMC9984207 DOI: 10.1111/cge.13716] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 01/07/2020] [Accepted: 01/23/2020] [Indexed: 01/04/2023]
Abstract
Although multigene panel testing (MGPT) is increasingly utilized in clinical practice, there remain limited data on patient-reported outcomes. BRCA 1/2 negative patients were contacted and offered MGPT. Patients completed pre- and posttest counseling, and surveys assessing cognitive, affective and behavioral outcomes at baseline, postdisclosure and 6 and 12 months. Of 317 eligible BRCA1/2 negative patients who discussed the study with research staff, 249 (79%) enrolled. Decliners were more likely to be older, non-White, and recruited by mail or email. Ninety-five percent of enrolled patients proceeded with MGPT. There were no significant changes in anxiety, depression, cancer specific distress or uncertainty postdisclosure. There were significant but small increases in knowledge, cancer-specific distress and depression at 6-12 months. Uncertainty declined over time. Those with a VUS had significant decreases in uncertainty but also small increases in cancer specific distress at 6 and 12 months. Among those with a positive result, medical management recommendations changed in 26% of cases and 2.6% of all tested. Most BRCA1/2 negative patients have favorable psychosocial outcomes after receipt of MGPT results, although small increases in depression and cancer-specific worry may exist and may vary by result. Medical management changed in few patients.
Collapse
Affiliation(s)
- Angela R. Bradbury
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA,Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, Pennsylvania, USA,Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Brian L. Egleston
- Fox Chase Cancer Center, Temple University Health System, Biostatistics and Bioinformatics Facility, Philadelphia, Pennsylvania, USA
| | - Linda J. Patrick-Miller
- Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
| | - Neil Rustgi
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Amanda Brandt
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Jamie Brower
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Laura DiGiovanni
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Dominique Fetzer
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Christopher Berkelbach
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Jessica M. Long
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Jacquelyn Powers
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Jill E. Stopfer
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Susan M. Domchek
- Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA,Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| |
Collapse
|
10
|
Langlois CM, Bradbury A, Wood EM, Roberts JS, Kim SYH, Riviere ME, Liu F, Reiman EM, Tariot PN, Karlawish J, Langbaum JB. Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS 2019; 5:705-716. [PMID: 31921963 PMCID: PMC6944715 DOI: 10.1016/j.trci.2019.09.013] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Introduction As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provide comprehensive standardized counseling and disclosure of apolipoprotein E (APOE) results efficiently, safely, and effectively in the context of AD prevention trials. Methods A multidisciplinary Genetic Testing, Counseling, and Disclosure Committee was established and charged with operationalizing the Alzheimer's Prevention Initiative (API) Genetic Counseling and Disclosure Process for use in the API Generation Program trials. The objective was to provide consistent information to research participants before and during the APOE counseling and disclosure session using standardized educational and session materials. Results The Genetic Testing, Counseling, and Disclosure Committee created a process consisting of eight components: requirements of APOE testing and reports, psychological readiness assessment, determination of AD risk estimates, guidance for identifying providers of disclosure, predisclosure education, APOE counseling and disclosure session materials, APOE counseling and disclosure session flow, and assessing APOE disclosure impact. Discussion The API Genetic Counseling and Disclosure Process provides a framework for large-scale disclosure of APOE genotype results to study participants and serves as a model for disclosure of biomarker results. The process provides education to participants about the meaning and implication(s) of their APOE results while also incorporating a comprehensive assessment of disclosure impact. Data assessing participant safety and psychological well-being before and after APOE disclosure are still being collected and will be presented in a future publication. Participants may need to learn their risk for Alzheimer's disease to enroll in studies. Alternatives to traditional models of apolipoprotein E counseling and disclosure are needed. An alternative process was developed by the Alzheimer's Prevention Initiative. This process has been implemented by the Alzheimer's Prevention Initiative Generation Program.
Collapse
Affiliation(s)
| | - Angela Bradbury
- Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA
| | - Elisabeth M Wood
- Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA
| | - J Scott Roberts
- Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | | | | | - Fonda Liu
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - Eric M Reiman
- Banner Alzheimer's Institute, Phoenix, AZ, USA.,Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, USA.,Department of Psychiatry, University of Arizona School of Medicine - Phoenix, Phoenix, AZ, USA.,Department of Psychiatry, University of Arizona, Tucson, AZ, USA.,Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.,Arizona Alzheimer's Consortium, Phoenix, AZ, USA
| | | | - Jason Karlawish
- Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA
| | | |
Collapse
|
11
|
Brédart A, Anota A, Dick J, Cano A, De Pauw A, Kop JL, Aaronson NK, Bleiker EM, Brunet J, Devilee P, Stoppa-Lyonnet D, Schmutzler R, Dolbeault S. The "Psychosocial Aspects in Hereditary Cancer" questionnaire in women attending breast cancer genetic clinics: Psychometric validation across French-, German- and Spanish-language versions. Eur J Cancer Care (Engl) 2019; 29:e13173. [PMID: 31571365 DOI: 10.1111/ecc.13173] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 05/23/2019] [Accepted: 09/04/2019] [Indexed: 11/30/2022]
Abstract
BACKGROUND We performed a comprehensive assessment of the psychometrics of the "Psychosocial Aspects in Hereditary Cancer" (PAHC) questionnaire in French, German and Spanish. METHODS Women consecutively approached in Cancer Genetic Clinics completed the PAHC, distress and satisfaction questionnaires at pre-testing (T1) and after test result disclosure (T2). In addition to standard psychometric attributes, we assessed the PAHC ability to respond to change (i.e. improvement or deterioration from T1 to T2) in perceived difficulties and computed minimal important differences (MID) in PAHC scores as compared with self-reported needs for additional counselling. RESULTS Of 738 eligible counselees, 214 (90%) in France (Paris), 301 (92%) in Germany (Cologne) and 133 (77%) in Spain (Barcelona) completed the PAHC. A six-factor revised PAHC model yielded acceptable CFA goodness-of-fit indexes and good all scales internal consistencies. PAHC scales demonstrated expected conceptual differences with distress and satisfaction with counselling. Different levels of psychosocial difficulties were evidenced between counselees' subgroups and over time (p-values < .05). MID estimates ranged from 8 to 15 for improvement and 9 to 21 for deterioration. CONCLUSION The PAHC French, German and Spanish versions are reliable and valid for evaluating the psychosocial difficulties of women at high BC risk attending genetic clinics.
Collapse
Affiliation(s)
- Anne Brédart
- Supportive Care Department, Psycho-oncology Unit, Psychopathology and Health Process Laboratory, EA 4047, Psychology Institute, Institut Curie, University Paris Descartes, Paris, France
| | - Amélie Anota
- Methodology and Quality of Life in Oncology unit (INSERM UMR 1098), University Hospital of Besançon and French National Platform Quality of Life and Cancer, Besançon, France
| | - Julia Dick
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Alejandra Cano
- Clinical and Health Psychology Department, University Autónoma of Barcelona, Barcelona, Spain
| | | | - Jean-Luc Kop
- Université de Lorraine, 2LPN (CEMA), Nancy, France
| | - Neil K Aaronson
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Eveline M Bleiker
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Joan Brunet
- Catalan Institute of Oncology, Barcelona, Spain
| | - Peter Devilee
- Department of Human Genetics & Division of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Rita Schmutzler
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Sylvie Dolbeault
- Institut Curie, Supportive Care Department, Psycho-oncology Unit, Paris and CESP, University Paris-Sud, UVSQ, INSERM, University Paris-Saclay, Villejuif, France
| |
Collapse
|
12
|
Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst 2019; 110:985-993. [PMID: 29490071 DOI: 10.1093/jnci/djy015] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Accepted: 01/18/2018] [Indexed: 12/16/2022] Open
Abstract
Background Germline genetic testing is standard practice in oncology. Outcomes of telephone disclosure of a wide range of cancer genetic test results, including multigene panel testing (MGPT) are unknown. Methods Patients undergoing cancer genetic testing were recruited to a multicenter, randomized, noninferiority trial (NCT01736345) comparing telephone disclosure (TD) of genetic test results with usual care, in-person disclosure (IPD) after tiered-binned in-person pretest counseling. Primary noninferiority outcomes included change in knowledge, state anxiety, and general anxiety. Secondary outcomes included cancer-specific distress, depression, uncertainty, satisfaction, and screening and risk-reducing surgery intentions. To declare noninferiority, we calculated the 98.3% one-sided confidence interval of the standardized effect; t tests were used for secondary subgroup analyses. Only noninferiority tests were one-sided, others were two-sided. Results A total of 1178 patients enrolled in the study. Two hundred eight (17.7%) participants declined random assignment due to a preference for in-person disclosure; 473 participants were randomly assigned to TD and 497 to IPD; 291 (30.0%) had MGPT. TD was noninferior to IPD for general and state anxiety and all secondary outcomes immediately postdisclosure. TD did not meet the noninferiority threshold for knowledge in the primary analysis, but it did meet the threshold in the multiple imputation analysis. In secondary analyses, there were no statistically significant differences between arms in screening and risk-reducing surgery intentions, and no statistically significant differences in outcomes by arm among those who had MGPT. In subgroup analyses, patients with a positive result had statistically significantly greater decreases in general anxiety with telephone disclosure (TD -0.37 vs IPD +0.87, P = .02). Conclusions Even in the era of multigene panel testing, these data suggest that telephone disclosure of cancer genetic test results is as an alternative to in-person disclosure for interested patients after in-person pretest counseling with a genetic counselor.
Collapse
Affiliation(s)
- Angela R Bradbury
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Linda J Patrick-Miller
- Division of Hematology-Oncology and Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL
| | - Brian L Egleston
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Michael J Hall
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Susan M Domchek
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Mary B Daly
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Pamela Ganschow
- Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - Generosa Grana
- Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Olufunmilayo I Olopade
- Division of Hematology-Oncology and Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL
| | - Dominique Fetzer
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Amanda Brandt
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Rachelle Chambers
- Division of Hematology-Oncology and Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL
| | - Dana F Clark
- Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Andrea Forman
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Rikki Gaber
- Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - Cassandra Gulden
- Division of Hematology-Oncology and Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL
| | - Janice Horte
- Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Jessica M Long
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Terra Lucas
- Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - Shreshtha Madaan
- Division of Hematology-Oncology and Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL
| | - Kristin Mattie
- Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Danielle McKenna
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Susan Montgomery
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Sarah Nielsen
- Division of Hematology-Oncology and Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL
| | - Jacquelyn Powers
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Kim Rainey
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Christina Rybak
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Michelle Savage
- Biostatistics and Bioinformatics Facility and Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA
| | - Christina Seelaus
- Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - Jessica Stoll
- Division of Hematology-Oncology and Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, and Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL
| | - Jill E Stopfer
- Division of Hematology-Oncology, Department of Medicine, Department of Medical Ethics and Health Policy, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
| | - Xinxin Shirley Yao
- Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ
| |
Collapse
|
13
|
Beri N, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao X(S, Bradbury AR. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet 2019; 95:293-301. [PMID: 30417332 PMCID: PMC6453119 DOI: 10.1111/cge.13474] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 11/02/2018] [Accepted: 11/06/2018] [Indexed: 01/04/2023]
Abstract
Telephone disclosure of cancer genetic test results is noninferior to in-person disclosure. However, how patients who prefer in-person communication of results differ from those who agree to telephone disclosure is unclear but important when considering delivery models for genetic medicine. Patients undergoing cancer genetic testing were recruited to a multicenter, randomized, noninferiority trial (NCT01736345) comparing telephone to in-person disclosure of genetic test results. We evaluated preferences for in-person disclosure, factors associated with this preference and outcomes compared to those who agreed to randomization. Among 1178 enrolled patients, 208 (18%) declined randomization, largely given a preference for in-person disclosure. These patients were more likely to be older (P = 0.007) and to have had multigene panel testing (P < 0.001). General anxiety (P = 0.007), state anxiety (P = 0.008), depression (P = 0.011), cancer-specific distress (P = 0.021) and uncertainty (P = 0.03) were higher after pretest counseling. After disclosure of results, they also had higher general anxiety (P = 0.003), depression (P = 0.002) and cancer-specific distress (P = 0.043). While telephone disclosure is a reasonable alternative to in-person disclosure in most patients, some patients have a strong preference for in-person communication. Patient age, distress and complexity of testing are important factors to consider and requests for in-person disclosure should be honored when possible.
Collapse
Affiliation(s)
- Nina Beri
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Linda J. Patrick-Miller
- Center for Clinical Cancer Genetics and Global Health, The
University of Chicago, Chicago, Illinois
| | - Brian L. Egleston
- Fox Chase Cancer Center, Temple University Health System,
Biostatistics and Bioinformatics Facility, Philadelphia, Pennsylvania
| | - Michael J. Hall
- Fox Chase Cancer Center, Temple University Health System,
Department of Medical Genetics, Philadelphia, Pennsylvania
| | - Susan M. Domchek
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Mary B. Daly
- Fox Chase Cancer Center, Temple University Health System,
Department of Medical Genetics, Philadelphia, Pennsylvania
| | - Pamela Ganschow
- Department of Internal Medicine, The John H. Stroger Jr.
Hospital of Cook County, Chicago, Illinois
| | - Generosa Grana
- Division of Hematology-Oncology, MD Anderson Cancer Center
at Cooper, Camden, New Jersey
| | - Olufunmilayo I. Olopade
- Center for Clinical Cancer Genetics and Global Health, The
University of Chicago, Chicago, Illinois
| | - Dominique Fetzer
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Amanda Brandt
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Rachelle Chambers
- Division of Hematology-Oncology, Department of Medicine,
The University of Chicago, Chicago, Illinois
| | - Dana F. Clark
- Division of Hematology-Oncology, MD Anderson Cancer Center
at Cooper, Camden, New Jersey
| | - Andrea Forman
- Fox Chase Cancer Center, Temple University Health System,
Department of Medical Genetics, Philadelphia, Pennsylvania
| | - Rikki Gaber
- Department of Internal Medicine, The John H. Stroger Jr.
Hospital of Cook County, Chicago, Illinois
| | - Cassandra Gulden
- Division of Hematology-Oncology, Department of Medicine,
The University of Chicago, Chicago, Illinois
| | - Janice Horte
- Division of Hematology-Oncology, MD Anderson Cancer Center
at Cooper, Camden, New Jersey
| | - Jessica Long
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Terra Lucas
- Department of Internal Medicine, The John H. Stroger Jr.
Hospital of Cook County, Chicago, Illinois
| | - Shreshtha Madaan
- Division of Hematology-Oncology, Department of Medicine,
The University of Chicago, Chicago, Illinois
| | - Kristin Mattie
- Division of Hematology-Oncology, MD Anderson Cancer Center
at Cooper, Camden, New Jersey
| | - Danielle McKenna
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Susan Montgomery
- Fox Chase Cancer Center, Temple University Health System,
Department of Medical Genetics, Philadelphia, Pennsylvania
| | - Sarah Nielsen
- Division of Hematology-Oncology, Department of Medicine,
The University of Chicago, Chicago, Illinois
| | - Jacquelyn Powers
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Kim Rainey
- Fox Chase Cancer Center, Temple University Health System,
Department of Medical Genetics, Philadelphia, Pennsylvania
| | - Christina Rybak
- Fox Chase Cancer Center, Temple University Health System,
Department of Medical Genetics, Philadelphia, Pennsylvania
| | - Michelle Savage
- Fox Chase Cancer Center, Temple University Health System,
Department of Medical Genetics, Philadelphia, Pennsylvania
| | - Christina Seelaus
- Department of Internal Medicine, The John H. Stroger Jr.
Hospital of Cook County, Chicago, Illinois
| | - Jessica Stoll
- Division of Hematology-Oncology, Department of Medicine,
The University of Chicago, Chicago, Illinois
| | - Jill E Stopfer
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
| | - Xinxin (Shirley) Yao
- Division of Hematology-Oncology, MD Anderson Cancer Center
at Cooper, Camden, New Jersey
| | - Angela R. Bradbury
- Department of Medicine, Division of Hematology-Oncology,
University of Pennsylvania, Philadelphia, Pennsylvania
- Abramson Cancer Center, University of Pennsylvania,
Philadelphia, Pennsylvania
- Department of Medical Ethics and Health Policy, University
of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
14
|
Hall MJ, Patrick-Miller LJ, Egleston BL, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao X(S, Bradbury AR. Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precis Oncol 2018; 2:PO.18.00199. [PMID: 31819920 PMCID: PMC6901130 DOI: 10.1200/po.18.00199] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Multigene panels (MGPs) are increasingly being used despite questions regarding their clinical utility and no standard approach to genetic counseling. How frequently genetic providers use MGP testing and how patient-reported outcomes (PROs) differ from targeted testing (eg, BRCA1/2 only) are unknown. METHODS We evaluated use of MGP testing and PROs in participants undergoing cancer genetic testing in the multicenter Communication of Genetic Test Results by Telephone study (ClinicalTrials.gov identifier: ), a randomized study of telephone versus in-person disclosure of genetic test results. PROs included genetic knowledge, general and state anxiety, depression, cancer-specific distress, uncertainty, and satisfaction. Genetic providers offered targeted or MGP testing based on clinical assessment. RESULTS Since the inclusion of MGP testing in 2014, 395 patients (66%) were offered MGP testing. MGP testing increased over time from 57% in 2014 to 66% in 2015 (P = .02) and varied by site (46% to 78%; P < .01). Being offered MGP testing was significantly associated with not having Ashkenazi Jewish ancestry, having a history of cancer, not having a mutation in the family, not having made a treatment decision, and study site. After demographic adjustment, patients offered MGP testing had lower general anxiety (P = .04), state anxiety (P = .03), depression (P = .04), and uncertainty (P = .05) pre-disclosure compared with patients offered targeted testing. State anxiety (P = .05) and cancer-specific distress (P = .05) were lower at disclosure in the MGP group. There was a greater increase in change in uncertainty (P = .04) among patients who underwent MGP testing. CONCLUSION MGP testing was more frequently offered to patients with lower anxiety, depression, and uncertainty and was associated with favorable outcomes, with the exception of a greater increase in uncertainty compared with patients who had targeted testing. Addressing uncertainty may be important as MGP testing is increasingly adopted.
Collapse
Affiliation(s)
- Michael J. Hall
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Linda J. Patrick-Miller
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Brian L. Egleston
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Susan M. Domchek
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Mary B. Daly
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Pamela Ganschow
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Generosa Grana
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Olufunmilayo I. Olopade
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Dominique Fetzer
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Amanda Brandt
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Rachelle Chambers
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Dana F. Clark
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Andrea Forman
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Rikki Gaber
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Cassandra Gulden
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Janice Horte
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Jessica M. Long
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Terra Lucas
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Shreshtha Madaan
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Kristin Mattie
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Danielle McKenna
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Susan Montgomery
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Sarah Nielsen
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Jacquelyn Powers
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Kim Rainey
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Christina Rybak
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Michelle Savage
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Christina Seelaus
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Jessica Stoll
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Jill E. Stopfer
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Xinxin (Shirley) Yao
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| | - Angela R. Bradbury
- Michael J. Hall, Brian L. Egleston, Mary B. Daly, Andrea Forman, Susan Montgomery, Kim Rainey, Christina Rybak, and Michelle Savage, Fox Chase Cancer Center, Temple University Health System; Susan M. Domchek, Dominique Fetzer, Amanda Brandt, Jessica M. Long, Danielle McKenna, Jacquelyn Powers, Jill E. Stopfer, and Angela R. Bradbury, University of Pennsylvania; Susan M. Domchek and Angela R. Bradbury, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Linda J. Patrick-Miller and Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics and Global Health, The University of Chicago; Pamela Ganschow, Rikki Gaber, Terra Lucas, and Christina Seelaus, The John H. Stroger Jr. Hospital of Cook County; Rachelle Chambers, Cassandra Gulden, Shreshtha Madaan, Sarah Nielsen, and Jessica Stoll, The University of Chicago, Chicago, IL; and Generosa Grana, Dana F. Clark, Janice Horte, Kristin Mattie, and Xinxin (Shirley) Yao, MD Anderson Cancer Center at Cooper, Camden, NJ
| |
Collapse
|
15
|
Bradbury AR, Patrick-Miller L, Egleston BL, Maxwell KN, DiGiovanni L, Brower J, Fetzer D, Bennett Gaieski J, Brandt A, McKenna D, Long J, Powers J, Stopfer JE, Nathanson KL, Domchek SM. Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precis Oncol 2018; 2. [PMID: 32095738 DOI: 10.1200/po.17.00250] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Purpose Understanding the outcomes of returning individual genetic research results to participants is critical because some genetic variants are found to be associated with health outcomes and have become available for clinical testing. Materials and Methods BRCA1/2-negative women with early-onset breast cancer, multiple primary cancers, or a family history of breast cancer who participated in a gene discovery cancer registry were offered the opportunity to learn their individual genetic research results of 24 breast cancer susceptibility genes with a genetic counselor after predisclosure genetic counseling. Outcomes included uptake of research results, knowledge, informed choice, psychosocial adjustment, uncertainty, satisfaction, and uptake of clinical confirmation testing. Results Four hundred two potential participants were contacted. One hundred ninety-four participants (48%) did not respond despite multiple attempts, and 85 participants (21%) actively or passively declined. One hundred seven participants (27%) elected for predisclosure counseling and were more likely to be younger, married, and white. Ninety percent of participants who had predisclosure counseling elected to receive their genetic research results, and 89% made an informed choice. Knowledge increased significantly after predisclosure counseling, and anxiety, intrusive cancer-specific distress, uncertainty, and depression declined significantly after receipt of results. General anxiety and intrusive cancer-specific distress declined significantly for both participants with a positive result and those with a negative result. Sixty-four percent of participants had clinical confirmation testing when recommended, including all participants with a mutation in a high-penetrance gene. Conclusion Uptake of genetic research results may be lower than anticipated by hypothetical reports and small select studies. Participants who elected to receive research results with genetic providers did not experience increases in distress or uncertainty, but not all patients return for confirmation testing.
Collapse
Affiliation(s)
- Angela R Bradbury
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Linda Patrick-Miller
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Brian L Egleston
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Kara N Maxwell
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Laura DiGiovanni
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Jamie Brower
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Dominique Fetzer
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Jill Bennett Gaieski
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Amanda Brandt
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Danielle McKenna
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Jessica Long
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Jacquelyn Powers
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Jill E Stopfer
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Katherine L Nathanson
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| | - Susan M Domchek
- Angela R. Bradbury, Kara N. Maxwell, Laura DiGiovanni, Jamie Brower, Dominique Fetzer, Jill Bennett Gaieski, Amanda Brandt, Danielle McKenna, Jessica Long, Jacquelyn Powers, Jill E. Stopfer, Katherine L. Nathanson, and Susan M. Domchek, Perelman School of Medicine at the University of Pennsylvania; Brian L. Egleston, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; and Linda Patrick-Miller, The University of Chicago, Chicago, IL
| |
Collapse
|
16
|
Patient-Centered Care in Breast Cancer Genetic Clinics. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2018; 15:ijerph15020319. [PMID: 29439543 PMCID: PMC5858388 DOI: 10.3390/ijerph15020319] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 02/01/2018] [Accepted: 02/07/2018] [Indexed: 12/30/2022]
Abstract
With advances in breast cancer (BC) gene panel testing, risk counseling has become increasingly complex, potentially leading to unmet psychosocial needs. We assessed psychosocial needs and correlates in women initiating testing for high genetic BC risk in clinics in France and Germany, and compared these results with data from a literature review. Among the 442 counselees consecutively approached, 212 (83%) in France and 180 (97%) in Germany, mostly BC patients (81% and 92%, respectively), returned the ‘Psychosocial Assessment in Hereditary Cancer’ questionnaire. Based on the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) BC risk estimation model, the mean BC lifetime risk estimates were 19% and 18% in France and Germany, respectively. In both countries, the most prevalent needs clustered around the “living with cancer” and “children-related issues” domains. In multivariate analyses, a higher number of psychosocial needs were significantly associated with younger age (b = −0.05), higher anxiety (b = 0.78), and having children (b = 1.51), but not with country, educational level, marital status, depression, or loss of a family member due to hereditary cancer. These results are in line with the literature review data. However, this review identified only seven studies that quantitatively addressed psychosocial needs in the BC genetic counseling setting. Current data lack understandings of how cancer risk counseling affects psychosocial needs, and improves patient-centered care in that setting.
Collapse
|
17
|
Cicero G, De Luca R, Dorangricchia P, Lo Coco G, Guarnaccia C, Fanale D, Calò V, Russo A. Risk Perception and Psychological Distress in Genetic Counselling for Hereditary Breast and/or Ovarian Cancer. J Genet Couns 2017; 26:999-1007. [PMID: 28283917 DOI: 10.1007/s10897-017-0072-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Accepted: 01/18/2017] [Indexed: 12/23/2022]
Abstract
Oncological Genetic Counselling (CGO) allows the identification of a genetic component that increases the risk of developing a cancer. Individuals' psychological reactions are influenced by both the content of the received information and the subjective perception of their own risk of becoming ill or being a carrier of a genetic mutation. This study included 120 participants who underwent genetic counselling for breast and/or ovarian cancer. The aim of the study was to examine the relation between their cancer risk perception and the genetic risk during CGO before receiving genetic test results, considering the influence of some psychological variables, in particular distress, anxiety and depression. Participants completed the following tools during a psychological interview: a socio-demographic form, Cancer Risk Perception (CRP) and Genetic Risk Perception (GRP), Hospital Anxiety and Depression Scale (HADS) and Distress Thermometer (DT). The data seem to confirm our hypothesis. Positive and significant correlations were found between the observed variables. Moreover, genetic risk perception determined an increase in depressive symptomatology and cancer risk perception led to an increase in anxious symptomatology, specifically in participants during cancer treatment. The present results suggest the importance of assessing genetic and cancer risk perception in individuals who undergo CGO, to identify those who are at risk of a decrease in psychological well-being and of developing greater psychological distress.
Collapse
Affiliation(s)
- G Cicero
- Department of Surgical, Oncology and Oral Sciences, University of Palermo, Via del Vespro, n. 129, 90127, Palermo, Italy.
| | - R De Luca
- Department of Surgical, Oncology and Oral Sciences, University of Palermo, Via del Vespro, n. 129, 90127, Palermo, Italy
| | - P Dorangricchia
- Department of Surgical, Oncology and Oral Sciences, University of Palermo, Via del Vespro, n. 129, 90127, Palermo, Italy
| | - G Lo Coco
- Department of Psychology and Educational Sciences, University of Palermo, Palermo, Italy
| | - C Guarnaccia
- Laboratoire Parisien de Psychologie Sociale, Université Paris 8 Vincennes Saint Denis, Saint Denis, France
| | - D Fanale
- Department of Surgical, Oncology and Oral Sciences, University of Palermo, Via del Vespro, n. 129, 90127, Palermo, Italy
| | - V Calò
- Department of Surgical, Oncology and Oral Sciences, University of Palermo, Via del Vespro, n. 129, 90127, Palermo, Italy
| | - A Russo
- Department of Surgical, Oncology and Oral Sciences, University of Palermo, Via del Vespro, n. 129, 90127, Palermo, Italy
| |
Collapse
|
18
|
Anxiety and depression symptoms among women attending group-based patient education courses for hereditary breast and ovarian cancer. Hered Cancer Clin Pract 2017; 15:2. [PMID: 28096903 PMCID: PMC5225510 DOI: 10.1186/s13053-016-0062-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Accepted: 12/30/2016] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Women carrying BRCA-mutations are facing significant challenges, including decision making regarding surveillance and risk-reducing surgery. They often report that they are left alone with these important decisions. In order to enhance the genetic counselling session we organized a group-based patient education (GPE) course for women with BRCA-mutations. The study aims were to characterize women attending a group-based patient education (GPE) course for hereditary breast and ovarian cancer, consider the usefulness of the course, evaluate symptoms of anxiety and depression among the participants, and finally investigate whether their levels of anxiety and depression changed from before to after the course session. METHODS A prospective study was conducted. Two weeks before (T1) and 2 weeks after (T2) attending the GPE-course the participants received questionnaires by mail. We collected information on demographic- and medical variables, anxiety and depression using Hospital Anxiety and Depression Scale (HADS), self-efficacy using The Bergen Genetic Counseling Self-Efficacy scale (BGCSES) and coping style using the Threatening Medical Situations Inventory (TMSI). A total of N = 100 (77% response rate) women participated at baseline and 75 (58% response rate) also completed post-course assessment. RESULTS The mean level of anxiety symptoms was elevated among participants but decreased significantly during follow-up. Lower anxiety symptom levels were associated with "longer time since disclosure of gene test result", "higher levels of self-efficacy" and having experienced "loss of a close relative due to breast or ovarian cancer". Lower depression symptom levels were associated with "higher levels of education" and "loss of a close relative due to breast or ovarian cancer". CONCLUSION The women in this study seemed to benefit from the GPE course. Women newly diagnosed with a BRCA mutation who reported lower levels of self-efficacy and lower levels of education were more vulnerable. These women need special attention.
Collapse
|
19
|
Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. Genet Med 2016; 19:754-762. [DOI: 10.1038/gim.2016.182] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Accepted: 09/13/2016] [Indexed: 12/20/2022] Open
|
20
|
Brédart A, Kop JL, De Pauw A, Caron O, Fajac A, Noguès C, Stoppa-Lyonnet D, Dolbeault S. Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result. Breast 2016; 31:121-127. [PMID: 27837705 DOI: 10.1016/j.breast.2016.10.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 10/27/2016] [Accepted: 10/28/2016] [Indexed: 01/28/2023] Open
Abstract
Information provision during BRCA1/2 genetic counseling is complex and expected to be increasingly so with gene panel testing. This prospective study evaluated whether genetic knowledge in counselees with breast cancer (BC) after a pre-test genetic counseling visit (T1) enhance their feeling of personal control while minimizing distress after the notification of BRCA1/2 result (T2). At T1, 243 (89% response rate) counselees completed questionnaires on genetic knowledge (BGKQ), perceived cancer genetic risk; of which, at T2, 180 (66%) completed the BGKQ again, scales of anxiety/depression, distress specific to genetic risk, and perceived control. Multilevel models were performed accounting for clinician, and testing an effect of knowledge on psychological outcomes according to the adequacy of counselees' perceived genetic predisposition to cancer. The mean knowledge score was moderate at T1, decreased while not significantly differing by BRCA1/2 test result at T2. Knowledge at T1 had no direct effect on psychological outcomes, but in counselees who over-estimated their cancer genetic risk, higher knowledge at T1 predicted higher specific distress at T2. In BC affected counselees who over-estimate their cancer genetic risk, higher BRCA1/2 pre-test genetic knowledge seem to lead to increased specific distress. Identifying these BC affected counselees who over-estimate their genetic cancer risk and helping them to interpret their genetic knowledge instead of providing them with exhaustive genetic information could minimize their distress after test result receipt.
Collapse
Affiliation(s)
- Anne Brédart
- Institut Curie, Supportive Care Department, Psycho-oncology Unit 26 rue d'Ulm, 75005 Paris Cedex 05, France; University Paris Descartes, 71, Avenue Edouard Vaillant, 92774 Boulogne-Billancourt, France.
| | - Jean-Luc Kop
- Université de Lorraine, Inter-Psy, Inter-Psy, 3 Place Godefroy de Bouillon, BP 33 97, 54 015 Nancy Cedex, France
| | - Antoine De Pauw
- Institut Curie, Cancer Genetic Clinic, 26 rue d'Ulm, 75005 Paris Cedex 05, France
| | - Olivier Caron
- Gustave Roussy Hôpital Universitaire, Cancer Genetic Clinic, 114 rue Ed Vaillant, 94 805 Villejuif, France
| | - Anne Fajac
- Hôpital Tenon Service d'Histologie-Biologie Tumorale, AP-HP, ER2 UPMC Université Pierre et Marie Curie, 4 rue de la Chine, 75020, France
| | - Catherine Noguès
- Institut Paoli-Calmettes, 232, Boulevard Sainte Margueritte, Marseille, France
| | | | - Sylvie Dolbeault
- Institut Curie, Supportive Care Department, Psycho-oncology Unit 26 rue d'Ulm, 75005 Paris Cedex 05, France; CESP, Univ. Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
21
|
Amara N, Blouin-Bougie J, Jbilou J, Halilem N, Simard J, Landry R. The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes. Fam Cancer 2016; 15:1-17. [PMID: 26334522 DOI: 10.1007/s10689-015-9835-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The aim of this paper is twofold: to analyze the genetic counseling process for breast cancer with a theoretical knowledge transfer lens and to compare generalists, medical specialists, and genetic counselors with regards to their genetic counseling practices. This paper presents the genetic counseling process occurring within a chain of value-adding activities of four main stages describing health professionals' clinical practices: (1) evaluation, (2) investigation, (3) information, and (4) decision. It also presents the results of a cross-sectional study based on a Canadian medical doctors and genetic counselors survey (n = 176) realized between July 2012 and March 2013. The statistical exercise included descriptive statistics, one-way ANOVA and post-hoc tests. The results indicate that even though all types of health professionals are involved in the entire process of genetic counseling for breast cancer, genetic counselors are more involved in the evaluation of breast cancer risk, while medical doctors are more active in the decision toward breast cancer risk management strategies. The results secondly demonstrate the relevance and the key role of genetic counselors in the care provided to women at-risk of familial breast cancer. This paper presents an integrative framework to understand the current process of genetic counseling for breast cancer in Canada, and to shed light on how and where health professionals contribute to the process. It also offers a starting point for assessing clinical practices in genetic counseling in order to establish more clearly where and to what extent efforts should be undertaken to implement future genetic services.
Collapse
Affiliation(s)
- Nabil Amara
- Department of Management, Pavillon Palasis-Prince, Laval University, 2325, rue de la Terrasse, Local 1516, Quebec, QC, G1V 0A6, Canada.
| | - Jolyane Blouin-Bougie
- Department of Management, Pavillon Palasis-Prince, Laval University, 2325, rue de la Terrasse, Local 1516, Quebec, QC, G1V 0A6, Canada.
| | - Jalila Jbilou
- New Brunswick Medical Training Centre and School of Psychology, University of Monction, Moncton, NB, Canada.
| | - Norrin Halilem
- Department of Management, Pavillon Palasis-Prince, Laval University, 2325, rue de la Terrasse, Local 1516, Quebec, QC, G1V 0A6, Canada.
| | - Jacques Simard
- Cancer Genomics Laboratory, Department of Molecular Medicine, Laval University, Quebec, QC, Canada.
| | - Réjean Landry
- Department of Management, Pavillon Palasis-Prince, Laval University, 2325, rue de la Terrasse, Local 1516, Quebec, QC, G1V 0A6, Canada.
| |
Collapse
|
22
|
van Bruinessen IR, van den Ende ITA, Visser LNC, van Dulmen S. The impact of watching educational video clips on analogue patients' physiological arousal and information recall. PATIENT EDUCATION AND COUNSELING 2016; 99:243-249. [PMID: 26427309 DOI: 10.1016/j.pec.2015.08.022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 07/21/2015] [Accepted: 08/15/2015] [Indexed: 06/05/2023]
Abstract
OBJECTIVE Investigating the influence of watching three educational patient-provider interactions on analogue patients' emotional arousal and information recall. METHODS In 75 analogue patients the emotional arousal was measured with physiological responses (electrodermal activity and heart rate) and self-reported arousal. RESULTS A moderate increased level of physiological arousal was measured but not too much to inflict emotional distress. Recall of information was within the pursued range. CONCLUSION Hence, physiological arousal is not expected to hinder the goals we pursue with our online intervention. PRACTICE IMPLICATIONS Still, developers and researchers should remain attentive to the self-reported (conscious) and hidden (subconscious) emotions evoked by the content of educational video clips presented in self-help interventions. A moderate increased level of arousal is preferred to increase the learning capacity. However, too much arousal may decrease the learning capacity and may cause distress, which should obviously be avoided for ethical reasons.
Collapse
Affiliation(s)
- I R van Bruinessen
- NIVEL (Netherlands Institute for Health Services Research), Utrecht, The Netherlands.
| | - I T A van den Ende
- NIVEL (Netherlands Institute for Health Services Research), Utrecht, The Netherlands
| | - L N C Visser
- AMC Medical Research, Academic Medical Center/University of Amsterdam, The Netherlands
| | - S van Dulmen
- NIVEL (Netherlands Institute for Health Services Research), Utrecht, The Netherlands; Department of Primary and Community Care, Radboud University Medical Centre, Nijmegen, The Netherlands; Faculty of Health Sciences, Buskerud and Vestfold University College, Drammen, Norway
| |
Collapse
|
23
|
Bradbury A, Patrick-Miller L, Harris D, Stevens E, Egleston B, Smith K, Mueller R, Brandt A, Stopfer J, Rauch S, Forman A, Kim R, Fetzer D, Fleisher L, Daly M, Domchek S. Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. J Med Internet Res 2016; 18:e23. [PMID: 26831751 PMCID: PMC4754531 DOI: 10.2196/jmir.4564] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Revised: 09/28/2015] [Accepted: 10/07/2015] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Videoconferencing has been used to expand medical services to low-access populations and could increase access to genetic services at community sites where in-person visits with genetic providers are not available. OBJECTIVE To evaluate the feasibility of, patient feedback of, and cognitive and affective responses to remote two-way videoconferencing (RVC) telegenetic services at multiple sociodemographically diverse community practices without access to genetic providers. METHODS Patients at 3 community sites in 2 US states outside the host center completed RVC pretest (visit 1, V1) and post-test (visit 2, V2) genetic counseling for cancer susceptibility. Surveys evaluated patient experiences, knowledge, satisfaction with telegenetic and cancer genetics services, anxiety, depression, and cancer worry. RESULTS A total of 82 out of 100 (82.0%) approached patients consented to RVC services. A total of 61 out of 82 patients (74%) completed pretest counseling and 41 out of 61 (67%) proceeded with testing and post-test counseling. A total of 4 out of 41 (10%) mutation carriers were identified: BRCA2, MSH2, and PMS2. Patients reported many advantages (eg, lower travel burden and convenience) and few disadvantages to RVC telegenetic services. Most patients reported feeling comfortable with the video camera--post-V1: 52/57 (91%); post-V2: 39/41 (95%)--and that their privacy was respected--post-V1: 56/57 (98%); post-V2: 40/41 (98%); however, some reported concerns that RVC might increase the risk of a confidentiality breach of their health information--post-V1: 14/57 (25%); post-V2: 12/41 (29%). While the majority of patients reported having no trouble seeing or hearing the genetic counselor--post-V1: 47/57 (82%); post-V2: 39/41 (95%)--51 out of 98 (52%) patients reported technical difficulties. Nonetheless, all patients reported being satisfied with genetic services. Compared to baseline, knowledge increased significantly after pretest counseling (+1.11 mean score, P=.005); satisfaction with telegenetic (+1.74 mean score, P=.02) and genetic services (+2.22 mean score, P=.001) increased after post-test counseling. General anxiety and depression decreased after pretest (-0.97 mean anxiety score, P=.003; -0.37 mean depression score, P=.046) and post-test counseling (-1.13 mean anxiety score, P=.003; -0.75 mean depression score, P=.01); state anxiety and cancer-specific worry did not significantly increase. CONCLUSIONS Remote videoconferencing telegenetic services are feasible, identify genetic carriers in community practices, and are associated with high patient satisfaction and favorable cognitive and affective outcomes, suggesting an innovative delivery model for further study to improve access to genetic providers and services. Potential barriers to dissemination include technology costs, unclear billing and reimbursement, and state requirements for provider licensure.
Collapse
Affiliation(s)
- Angela Bradbury
- Division of Hematology-Oncology, Department of Medicine, The University of Pennsylvania, Philadelphia, PA, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Zierhut HA, Shannon KM, Cragun DL, Cohen SA. Elucidating Genetic Counseling Outcomes from the Perspective of Genetic Counselors. J Genet Couns 2016; 25:993-1001. [DOI: 10.1007/s10897-015-9930-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 12/20/2015] [Indexed: 12/01/2022]
|
25
|
Martin L, Gitsels-van der Wal JT, Pereboom MTR, Spelten ER, Hutton EK, van Dulmen S. Clients' psychosocial communication and midwives' verbal and nonverbal communication during prenatal counseling for anomaly screening. PATIENT EDUCATION AND COUNSELING 2016; 99:85-91. [PMID: 26298217 DOI: 10.1016/j.pec.2015.07.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 07/17/2015] [Accepted: 07/18/2015] [Indexed: 06/04/2023]
Abstract
OBJECTIVES This study focuses on facilitation of clients' psychosocial communication during prenatal counseling for fetal anomaly screening. We assessed how psychosocial communication by clients is related to midwives' psychosocial and affective communication, client-directed gaze and counseling duration. METHODS During 184 videotaped prenatal counseling consultations with 20 Dutch midwives, verbal psychosocial and affective behavior was measured by the Roter Interaction Analysis System (RIAS). We rated the duration of client-directed gaze. We performed multilevel analyses to assess the relation between clients' psychosocial communication and midwives' psychosocial and affective communication, client-directed gaze and counseling duration. RESULTS Clients' psychosocial communication was higher if midwives' asked more psychosocial questions and showed more affective behavior (β=0.90; CI: 0.45-1.35; p<0.00 and β=1.32; CI: 0.18-2.47; p=0.025, respectively). Clients "psychosocial communication was not related to midwives" client-directed gaze. Additionally, psychosocial communication by clients was directly, positively related to the counseling duration (β=0.59; CI: 0.20-099; p=0.004). CONCLUSIONS In contrast with our expectations, midwives' client-directed gaze was not related with psychosocial communication of clients. PRACTICE IMPLICATIONS In addition to asking psychosocial questions, our study shows that midwives' affective behavior and counseling duration is likely to encourage client's psychosocial communication, known to be especially important for facilitating decision-making.
Collapse
Affiliation(s)
- Linda Martin
- Department of Midwifery Science, AVAG and the EMGO(+) Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands.
| | - Janneke T Gitsels-van der Wal
- Department of Midwifery Science, AVAG and the EMGO(+) Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands; Faculty of Theology, VU University, Amsterdam, Netherlands
| | - Monique T R Pereboom
- Department of Midwifery Science, AVAG and the EMGO(+) Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands
| | - Evelien R Spelten
- Department of Midwifery Science, AVAG and the EMGO(+) Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
| | - Eileen K Hutton
- Department of Midwifery Science, AVAG and the EMGO(+) Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands; Obstetrics & Gynecology, Midwifery Education Program, McMaster University, Hamilton, Ontario, Canada
| | - Sandra van Dulmen
- NIVEL (Netherlands Institute for Health Services Research), Utrecht, Netherlands; Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, Netherlands; Faculty of Health Sciences, Buskerud and Vestfold University College, Drammen, Norway
| |
Collapse
|
26
|
Feng R, Shen X, Chai J, Chen P, Cheng J, Liang H, Zhao T, Sha R, Li K, Wang D. Assessment and model guided cancer screening promotion by village doctors in China: a randomized controlled trial protocol. BMC Cancer 2015; 15:674. [PMID: 26458906 PMCID: PMC4603763 DOI: 10.1186/s12885-015-1688-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2014] [Accepted: 10/07/2015] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Proven cost-effectiveness contrasted by low uptake of cancer screening (CS) calls for new methodologies promoting the service. Contemporary interventions in this regard relies primarily on strategies targeting general or specific groups with limited attention being paid to individualized approaches. This trial tests a novel package promoting CS utilization via continuous and tailored counseling delivered by primary caregivers. It aims at demonstrating that high risk individuals in the intervention arm will, compared to those in the delayed intervention condition, show increased use of CS service. METHODS/DESIGN The trial adopts a quasi-randomized controlled trial design and involves 2160 high risk individuals selected, via rapid and detailed risk assessments, from about 72,000 farmers aged 35+ in 36 administrative villages randomized into equal intervention and delayed intervention arms. The CS intervention package uses: a) village doctors and village clinics to deliver personalized and thus relatively sophisticated CS counseling; b) two-stage risk assessment models in identifying high risk individuals to focus the intervention on the most needed; c) standardized operation procedures to guide conduct of counseling; d) real-time effectiveness and quality monitoring to leverage continuous improvement; e) web-based electronic system to enable prioritizing complex determinants of CS uptake and tailoring counseling sessions to the changing needs of individual farmers. The intervention arm receives baseline and semiannual follow up evaluations plus CS counseling for 5 years; while the delayed intervention arm, only the same baseline and follow-up evaluations for the first 5 years and CS counseling starting from the 6th year if the intervention proved effective. Evaluation measures include: CS uptake by high risk farmers and changes in their knowledge, perceptions and self-efficacy about CS. DISCUSSION Given the complexity and heterogeneity in the determinant system of individual CS service seeking behavior, personalized interventions may prove to be an effective strategy. The current trial distinguishes itself from previous ones in that it not only adopts a personalized strategy but also introduces a package of pragmatic solutions based on proven theories for tackling potential barriers and incorporating key success factors in a synergetic way toward low cost, effective and sustainable CS promotion. TRIAL REGISTRATION ISRCTN33269053.
Collapse
Affiliation(s)
- Rui Feng
- Department of Literature Review and Analysis, Library of Anhui Medical University, Hefei, Anhui, China.
| | - Xingrong Shen
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Jing Chai
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Penglai Chen
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Jing Cheng
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Han Liang
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Ting Zhao
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Rui Sha
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Kaichun Li
- Luan Center for Disease Control and Prevention, Luan, Anhui, China.
| | - Debin Wang
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
- Collaboration Center for Cancer Control, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
| |
Collapse
|
27
|
Redlinger-Grosse K, Veach PM, Cohen S, LeRoy BS, MacFarlane IM, Zierhut H. Defining Our Clinical Practice: The Identification of Genetic Counseling Outcomes Utilizing the Reciprocal Engagement Model. J Genet Couns 2015. [PMID: 26204965 DOI: 10.1007/s10897-015-9864-2] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The need for evidence-based medicine, including comparative effectiveness studies and patient-centered outcomes research, has become a major healthcare focus. To date, a comprehensive list of genetic counseling outcomes, as espoused by genetic counselors, has not been established and thus, identification of outcomes unique to genetic counseling services has become a priority for the National Society of Genetic Counselors (NSGC). The purpose of this study was to take a critical first step at identifying a more comprehensive list of genetic counseling outcomes. This paper describes the results of a focus group study using the Reciprocal-Engagement Model (REM) as a framework to characterize patient-centered outcomes of genetic counseling clinical practice. Five focus groups were conducted with 27 peer nominated participants who were clinical genetic counselors, genetic counseling program directors, and/or outcomes researchers in genetic counseling. Members of each focus group were asked to identify genetic counseling outcomes for four to five of the 17 goals of the REM. A theory-driven, thematic analysis of focus group data yielded 194 genetic counseling outcomes across the 17 goals. Participants noted some concerns about how genetic counseling outcomes will be measured and evaluated given varying stakeholders and the long-term nature of genetic concerns. The present results provide a list of outcomes for use in future genetic counseling outcomes research and for empirically-supported clinical interventions.
Collapse
Affiliation(s)
- Krista Redlinger-Grosse
- Department of Educational Psychology, University of Minnesota, 250 Education Sciences Building, 56 E. River Road, Minneapolis, MN, 55455, USA.
| | - Patricia McCarthy Veach
- Department of Educational Psychology, University of Minnesota, 250 Education Sciences Building, 56 E. River Road, Minneapolis, MN, 55455, USA
| | - Stephanie Cohen
- Cancer Genetics Risk Assessment Program, St. Vincent Hospital, Indianapolis, IN, USA
| | - Bonnie S LeRoy
- Department of Genetics, Cell Biology, and Development, Institute of Human Genetics, University of Minnesota, Minneapolis, MN, USA
| | | | - Heather Zierhut
- Department of Genetics, Cell Biology, and Development, Institute of Human Genetics, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
28
|
Otten E, Birnie E, Ranchor AV, van Langen IM. Telegenetics use in presymptomatic genetic counselling: patient evaluations on satisfaction and quality of care. Eur J Hum Genet 2015; 24:513-20. [PMID: 26173963 DOI: 10.1038/ejhg.2015.164] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Revised: 05/07/2015] [Accepted: 05/27/2015] [Indexed: 11/10/2022] Open
Abstract
In recent years, online counselling has been introduced in clinical genetics to increase patients' access to care and to reduce time and cost for both patients and professionals. Most telegenetics reports so far evaluated online oncogenetic counselling at remote health centres in regions with large travelling distances, generally showing positive patient outcomes. We think online counselling--including the use of supportive tools that are also available during in-person counseling--of presymptomatic patients in their homes can also be feasible and valuable for patients in relatively small regions. We performed a single-centre pilot study of online genetic counselling for 57 patients who were presymptomatic cardiogenetic (n=17), presymptomatic oncogenetic (n=34) and prenatal (3 couples). One-third of presymptomatic patients we approached consented to online counselling. Patient evaluations of practical aspects, satisfaction and psychological outcomes were assessed and compared with a matched control group. Patients managed to fulfil the preparations, were significantly more satisfied with their counsellor and counselling session than controls and were satisfied with the online counselling more than they expected to be beforehand. Psychological outcomes (decreased anxiety and increased control) did not differ with control patients. Technical problems occurred in almost half of online sessions. Nonetheless, online counselling in patients' homes proved to be feasible and was appreciated by a substantial part of presymptomatic patients at our genetics centre in the Netherlands. Based on these outcomes, we conclude online counselling can be a valuable addition to existing counselling options in regular patient care.
Collapse
Affiliation(s)
- Ellen Otten
- University of Groningen, University Medical Centre Groningen, Department of Genetics, Groningen, The Netherlands
| | - Erwin Birnie
- University of Groningen, University Medical Centre Groningen, Department of Genetics, Groningen, The Netherlands
| | - Adelita V Ranchor
- Department of Health Psychology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
| | - Irene M van Langen
- University of Groningen, University Medical Centre Groningen, Department of Genetics, Groningen, The Netherlands
| |
Collapse
|
29
|
Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genet Med 2015; 18:25-33. [PMID: 25834950 DOI: 10.1038/gim.2015.19] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Accepted: 01/19/2015] [Indexed: 01/18/2023] Open
Abstract
PURPOSE The risks, benefits, and utilities of multiplex panels for breast cancer susceptibility are unknown, and new counseling and informed consent models are needed. We sought to obtain patient feedback and early outcome data with a novel tiered-binned model for multiplex testing. METHODS BRCA1/2-negative and untested patients completed pre- and posttest counseling and surveys evaluating testing experiences and cognitive and affective responses to multiplex testing. RESULTS Of 73 patients, 49 (67%) completed pretest counseling. BRCA1/2-negative patients were more likely to proceed with multiplex testing (86%) than those untested for BRCA1/2 (43%; P < 0.01). Many patients declining testing reported concern for uncertainty and distress. Most patients would not change anything about their pre- (76%) or posttest (89%) counseling sessions. Thirty-three patients (72%) were classified as making an informed choice, including 81% of those who proceeded with multiplex testing. Knowledge increased significantly. Anxiety, depression, uncertainty, and cancer worry did not significantly increase with multiplex testing. CONCLUSION Some patients, particularly those without prior BRCA1/2 testing, decline multiplex testing. Most patients who proceeded with testing did not experience negative psychological responses, but larger studies are needed. The tiered-binned approach is an innovative genetic counseling and informed consent model for further study in the era of multiplex testing.Genet Med 18 1, 25-33.
Collapse
|
30
|
Eijzenga W, Aaronson NK, Hahn DEE, Sidharta GN, van der Kolk LE, Velthuizen ME, Ausems MGEM, Bleiker EMA. Effect of routine assessment of specific psychosocial problems on personalized communication, counselors’ awareness, and distress levels in cancer genetic counseling practice: a randomized controlled trial. J Clin Oncol 2015; 32:2998-3004. [PMID: 25049325 DOI: 10.1200/jco.2014.55.4576] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This study evaluated the efficacy of a cancer genetics–specific questionnaire in facilitating communication about, awareness of, and management of psychosocial problems, as well as in lowering distress levels. METHODS Individuals referred to genetic counseling for cancer at two family cancer clinics in The Netherlands were randomly assigned to an intervention or a control group. All participants completed the psychosocial questionnaire before counseling. In the intervention group, the counselors received the results of this questionnaire before the counseling session. All sessions were audiotaped for content analysis. Primary outcomes were the frequency with which psychosocial problems were discussed, the genetic counselors’ awareness of these problems, and their management. Secondary outcomes included cancer worries and psychological distress, duration and dynamics of the counseling, and satisfaction. RESULTS The frequency with which psychosocial problems were discussed with 246 participating counselees was significantly higher in the intervention group (n = 127) than in the control group (n =119; P = .004), as was the counselors’ awareness of psychosocial problems regarding hereditary predisposition (P < .001), living with cancer (P = .01), and general emotions (P < .001). Counselors initiated more discussion of psychosocial problems in the intervention group (P < .001), without affecting the length of the counseling session. No significant differences were found on management (P = .19). The intervention group reported significantly lower levels of cancer worries (p = .005) and distress (p = .02) after counseling. CONCLUSION The routine assessment of psychosocial problems by questionnaire facilitates genetic counselors’ recognition and discussion of their clients’ psychosocial problems and reduces clients’ distress levels.
Collapse
|
31
|
A group approach to genetic counselling of cardiomyopathy patients: satisfaction and psychological outcomes sufficient for further implementation. Eur J Hum Genet 2015; 23:1462-7. [PMID: 25649380 PMCID: PMC4613479 DOI: 10.1038/ejhg.2015.10] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Revised: 12/22/2014] [Accepted: 01/07/2015] [Indexed: 11/11/2022] Open
Abstract
The introduction of next-generation sequencing in everyday clinical genetics practise is increasing the number of genetic disorders that can be confirmed at DNA-level, and consequently increases the possibilities for cascade screening. This leads to a greater need for genetic counselling, whereas the number of professionals available to provide this is limited. We therefore piloted group genetic counselling for symptomatic cardiomyopathy patients at regional hospitals, to assess whether this could be an acceptable alternative to individual counselling. We performed a cohort study with pre- and post-counselling patient measurements using questionnaires, supplemented with evaluations of the group counselling format by the professionals involved. Patients from eight regional hospitals in the northern part of the Netherlands were included. Questionnaires comprised patient characteristics, psychological measures (personal perceived control (PPC), state and trait anxiety inventory (STAI)), and satisfaction with counsellors, counselling content and design. In total, 82 patients (mean age 57.5 year) attended one of 13 group sessions. Median PPC and STAI scores showed significantly higher control and lower anxiety after the counselling. Patients reported they were satisfied with the counsellors, and almost 75% of patients were satisfied with the group counselling. Regional professionals were also, overall, satisfied with the group sessions. The genetics professionals were less satisfied, mainly because of their perceived large time investment and less-than-expected group interaction. Hence, a group approach to cardiogenetic counselling is feasible, accessible, and psychologically effective, and could be one possible approach to counselling the increasing patient numbers in cardiogenetics.
Collapse
|
32
|
Paul J, Metcalfe S, Stirling L, Wilson B, Hodgson J. Analyzing communication in genetic consultations--a systematic review. PATIENT EDUCATION AND COUNSELING 2015; 98:15-33. [PMID: 25312331 DOI: 10.1016/j.pec.2014.09.017] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Revised: 08/21/2014] [Accepted: 09/21/2014] [Indexed: 06/04/2023]
Abstract
OBJECTIVE To systematically review studies that have analyzed communication within medical consultations involving genetic specialists and report on their findings and design. METHODS Drawing from PRISMA and appropriate guidelines for reviewing qualitative research, a systematic search of seven databases was conducted, followed by selection of studies for inclusion based on a set of criteria. Three authors conducted data extraction and narrative synthesis. RESULTS Twenty-two studies were identified and were heterogeneous in setting, design, and methods, with many including limited descriptions of health professionals involved. Despite this variability, studies generally pursued the following three main objectives: searching for structural patterns within consultations, investigating communication and genetic counseling concepts, and linking process with input- and outcome-measures. Structural patterns identified included clinician dialog dominating consultations, and talk being mostly biomedical. Counseling and communication concepts investigated were: risk communication, the negotiation of power and knowledge, and adherence to genetic counseling ideals. Attempts to link consultation data to input- or outcome-measures were often unsuccessful. CONCLUSION More interdisciplinary research, grounded in appropriate theoretical frameworks, is needed to explore inherent complexities in this setting. PRACTICE IMPLICATIONS Findings from this review can be used to guide the design of future research into the process of genetic consultations.
Collapse
Affiliation(s)
- Jean Paul
- Genetics Education and Health Research, Murdoch Childrens Research Institute, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Melbourne, Australia; School of Languages and Linguistics, The University of Melbourne, Melbourne, Australia
| | - Sylvia Metcalfe
- Genetics Education and Health Research, Murdoch Childrens Research Institute, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Melbourne, Australia
| | - Lesley Stirling
- School of Languages and Linguistics, The University of Melbourne, Melbourne, Australia
| | - Brenda Wilson
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada
| | - Jan Hodgson
- Genetics Education and Health Research, Murdoch Childrens Research Institute, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
| |
Collapse
|
33
|
Patrick-Miller LJ, Egleston BL, Fetzer D, Forman A, Bealin L, Rybak C, Peterson C, Corbman M, Albarracin J, Stevens E, Daly MB, Bradbury AR. Development of a communication protocol for telephone disclosure of genetic test results for cancer predisposition. JMIR Res Protoc 2014; 3:e49. [PMID: 25355401 PMCID: PMC4259920 DOI: 10.2196/resprot.3337] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 06/12/2014] [Accepted: 07/18/2014] [Indexed: 12/26/2022] Open
Abstract
Background Dissemination of genetic testing for disease susceptibility, one application of “personalized medicine”, holds the potential to empower patients and providers through informed risk reduction and prevention recommendations. Genetic testing has become a standard practice in cancer prevention for high-risk populations. Heightened consumer awareness of “cancer genes” and genes for other diseases (eg, cardiovascular and Alzheimer’s disease), as well as the burgeoning availability of increasingly complex genomic tests (ie, multi-gene, whole-exome and -genome sequencing), has escalated interest in and demand for genetic risk assessment and the specialists who provide it. Increasing demand is expected to surpass access to genetic specialists. Thus, there is urgent need to develop effective and efficient models of delivery of genetic information that comparably balance the risks and benefits to the current standard of in-person communication. Objective The aim of this pilot study was to develop and evaluate a theoretically grounded and rigorously developed protocol for telephone communication of BRCA1/2 (breast cancer) test results that might be generalizable to genetic testing for other hereditary cancer and noncancer syndromes. Methods Stakeholder data, health communication literature, and our theoretical model grounded in Self-Regulation Theory of Health Behavior were used to develop a telephone communication protocol for the communication of BRCA1/2 genetic test results. Framework analysis of selected audiotapes of disclosure sessions and stakeholders’ feedback were utilized to evaluate the efficacy and inform refinements to this protocol. Results Stakeholder feedback (n=86) and audiotapes (38%, 33/86) of telephone disclosures revealed perceived disadvantages and challenges including environmental factors (eg, non-private environment), patient-related factors (eg, low health literacy), testing-related factors (eg, additional testing needed), and communication factors (eg, no visual cues). Resulting modifications to the communication protocol for BRCA1/2 test results included clarified patient instructions, scheduled appointments, refined visual aids, expanded disclosure checklist items, and enhanced provider training. Conclusions Analyses of stakeholders’ experiences and audiotapes of telephone disclosure of BRCA1/2 test results informed revisions to communication strategies and a protocol to enhance patient outcomes when utilizing telephone to disclose genetic test results.
Collapse
Affiliation(s)
- Linda J Patrick-Miller
- Department of Medicine, Division of Hematology-Oncology, Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, IL, United States.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Albada A, Ausems MGEM, van Dulmen S. Counselee participation in follow-up breast cancer genetic counselling visits and associations with achievement of the preferred role, cognitive outcomes, risk perception alignment and perceived personal control. Soc Sci Med 2014; 116:178-86. [PMID: 25016325 DOI: 10.1016/j.socscimed.2014.07.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Revised: 06/02/2014] [Accepted: 07/05/2014] [Indexed: 11/29/2022]
Abstract
The purpose of the study was to assess the counselee participation in the follow-up visits, compared to the first visits, for breast cancer genetic counselling and to explore associations with counselees' achievement of their preferred role in decision making, information recall, knowledge, risk perception alignment and perceived personal control. First and follow-up visits for breast cancer genetic counselling of 96 counselees of a Dutch genetics center were videotaped (2008-2010). Counselees completed questionnaires before counselling (T1), after the follow-up visit (T2) and one year after the follow-up visit (T3). Consultations were rated with the Roter Interaction Analysis System (RIAS). Counselee participation was measured as the percentage of counselee utterances, the percentage of counselee questions and the interactivity (number of turns per minute). Follow-up visits had higher levels of counselee participation than first visits as assessed by the percentage of counselee talk, the interactivity and counselee questions. More counselee talk in the follow-up visit was related to higher achievement of the preferred role (T2) and higher perceived personal control (T3). Higher interactivity in the follow-up visit was related to lower achievement of the preferred role in decision making and lower information recall (T2). There were no significant associations with the percentage of questions asked and none of the participation measures was related to knowledge, risk perception alignment and perceived personal control (T2). In line with the interviewing admonishment 'talk less and listen more', the only assessment of counselee participation associated to better outcomes is the percentage of counselee talk. High interactivity might be associated with lower recall in breast cancer genetic counselees who are generally highly educated. However, this study was limited by a small sample size and a heterogeneous group of counselees. Research is needed on the interactions causing interactivity and its relationships with involvement in decision making and recall.
Collapse
Affiliation(s)
- Akke Albada
- Department of Medical Genetics, University Medical Centre Utrecht, Postbus 85500, 3508 AB Utrecht, The Netherlands; NIVEL (Netherlands Institute for Health Services Research), Utrecht, The Netherlands.
| | - Margreet G E M Ausems
- Department of Medical Genetics, University Medical Centre Utrecht, Postbus 85500, 3508 AB Utrecht, The Netherlands
| | - Sandra van Dulmen
- NIVEL (Netherlands Institute for Health Services Research), Utrecht, The Netherlands; Department of Primary and Community Care, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Health Sciences, Buskerud University College, Drammen, Norway
| |
Collapse
|
35
|
Earl T, Fortuna LR, Gao S, Williams DR, Neighbors HW, Takeuchi D, Alegría M. An exploration of how psychotic-like symptoms are experienced, endorsed, and understood from the National Latino and Asian American Study and National Survey of American Life. ETHNICITY & HEALTH 2014; 20:273-92. [PMID: 24920148 PMCID: PMC4930554 DOI: 10.1080/13557858.2014.921888] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/22/2012] [Accepted: 02/28/2014] [Indexed: 06/03/2023]
Abstract
OBJECTIVE . To examine racial-ethnic differences in the endorsement and attribution of psychotic-like symptoms in a nationally representative sample of African-Americans, Asians, Caribbean Blacks, and Latinos living in the USA. DESIGN Data were drawn from a total of 979 respondents who endorsed psychotic-like symptoms as part of the National Latino and Asian American Study (NLAAS) and the National Survey of American Life (NSAL). We use a mixed qualitative and quantitative analytical approach to examine sociodemographic and ethnic variations in the prevalence and attributions of hallucinations and other psychotic-like symptoms in the NLAAS and NSAL. The lifetime presence of psychotic-like symptoms was assessed using the World Health Organization Composite International Diagnostic Interview (WMH-CIDI) psychotic symptom screener. We used logistic regression models to examine the probability of endorsing the four most frequently occurring thematic categories for psychotic-like experiences by race/ethnicity (n > 100). We used qualitative methods to explore common themes from participant responses to open ended questions on their attributions for psychotic-like symptoms. RESULTS African-Americans were significantly less likely to endorse visual hallucinations compared to Caribbean Blacks (73.7% and 89.3%, p < .001), but they endorsed auditory hallucinations symptoms more than Caribbean Blacks (43.1% and 25.7, p < .05). Endorsing delusions of reference and thought insertion/withdrawal were more prevalent for Latinos than for African-Americans (11% and 4.7%, p < .05; 6.3% and 2.7%, p < .05, respectively). Attribution themes included: supernatural, ghosts/unidentified beings, death and dying, spirituality or religiosity, premonitions, familial and other. Respondents differed by race/ethnicity in the attributions given to psychotic like symptoms. CONCLUSION Findings suggest that variations exist by race/ethnicity in both psychotic-like symptom endorsement and in self-reported attributions/understandings for these symptoms on a psychosis screening instrument. Ethnic/racial differences could result from culturally sanctioned beliefs and idioms of distress that deserve more attention in conducting culturally informed and responsive screening, assessment and treatment.
Collapse
Affiliation(s)
- Tara Earl
- Health Education and Social Programs, Division of Public Health and Survey Research, ICF International, Inc., Atlanta, GA
| | - Lisa R. Fortuna
- Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA
| | - Shan Gao
- Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY
| | - David R. Williams
- Harvard School of Public Health, Department of Society, Human Development and Health, Boston, MA
| | | | - David Takeuchi
- Graduate School of Social Work, Boston College, Chestnut Hill, MA
| | - Margarita Alegría
- Center for Multicultural Mental Health Research, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA
| |
Collapse
|
36
|
Kelly KM, Ellington L, Schoenberg N, Agarwal P, Jackson T, Dickinson S, Abraham J, Paskett ED, Leventhal H, Andrykowski M. Linking genetic counseling content to short-term outcomes in individuals at elevated breast cancer risk. J Genet Couns 2014; 23:838-48. [PMID: 24671341 DOI: 10.1007/s10897-014-9705-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Accepted: 02/20/2014] [Indexed: 11/26/2022]
Abstract
Few studies have linked actual genetic counseling content to short-term outcomes. Using the Self-regulation Model, the impact of cognitive and affective content in genetic counseling on short-term outcomes was studied in individuals at elevated risk of familial breast-ovarian cancer. Surveys assessed dependent variables: distress, perceived risk, and 6 knowledge measures (Meaning of Positive Test; Meaning of Negative Test; Personal Behavior; Practitioner Knowledge; Mechanisms of Cancer Inheritance; Frequency of Inherited Cancer) measured at pre- and post-counseling. Proportion of participant cognitive and affective and counselor cognitive and affective content during sessions (using LIWC software) were predictors in regressions. Knowledge increased for 5 measures and decreased for Personal Behavior, Distress and Perceived Risk. Controlling for age and education, results were significant/marginally significant for three measures. More counselor content was associated with decreases in knowledge of Personal Behavior. More participant and less counselor affective content was associated with gains in Practitioner Knowledge. More counselor cognitive, and interaction of counselor cognitive and affective content, were associated with higher perceived risk. Genetic counselors dominate the content of counseling sessions. Therefore, their content is tied more closely to short term outcomes than participant content. A lack of patient communication in sessions may pose problems for understanding of complex concepts.
Collapse
Affiliation(s)
- Kimberly M Kelly
- School of Pharmacy, West Virginia University, Morgantown, WV, USA,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Patrick-Miller L, Egleston BL, Daly M, Stevens E, Fetzer D, Forman A, Bealin L, Rybak C, Peterson C, Corbman M, Bradbury AR. Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results. PATIENT EDUCATION AND COUNSELING 2013; 93:413-419. [PMID: 24075727 PMCID: PMC4199583 DOI: 10.1016/j.pec.2013.08.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2012] [Revised: 08/05/2013] [Accepted: 08/11/2013] [Indexed: 06/02/2023]
Abstract
OBJECTIVES With an increasing demand for genetic services, effective and efficient delivery models for genetic testing are needed. METHODS In this prospective single-arm communication study, participants received clinical BRCA1/2 results by telephone with a genetic counselor and completed surveys at baseline, after telephone disclosure (TD) and after in-person clinical follow-up. RESULTS Sixty percent of women agreed to participate; 73% of decliners preferred in-person communication. Anxiety decreased from baseline to post-TD (p=0.03) and satisfaction increased (p<0.01). Knowledge did not change significantly from baseline to post-TD, but was higher post-clinical follow-up (p=0.04). Cancer patients had greater declines in state anxiety and African-American participants reported less increase in satisfaction. 28% of participants did not return for in-person clinical follow-up, particularly those with less formal education, and higher post-disclosure anxiety and depression (p<0.01). CONCLUSIONS Telephone disclosure of BRCA1/2 test results may not be associated with negative cognitive and affective responses among willing patients, although some subgroups may experience less favorable responses. Some patients do not return for in-person clinical follow-up and longitudinal outcomes are unknown. PRACTICE IMPLICATIONS Further evaluation of longitudinal outcomes of telephone disclosure and differences among subgroups can inform how to best incorporate telephone communication into delivery of genetic services.
Collapse
Affiliation(s)
- Linda Patrick-Miller
- Department of Medicine, Division of Hematology–Oncology, The University of Chicago, Chicago, USA
- Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, USA
| | | | - Mary Daly
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | - Evelyn Stevens
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | - Dominique Fetzer
- Department of Medicine, Division of Hematology–Oncology, University of Pennsylvania, Philadelphia, USA
| | - Andrea Forman
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | - Lisa Bealin
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | - Christina Rybak
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | - Candace Peterson
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | - Melanie Corbman
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | - Angela R. Bradbury
- Department of Medicine, Division of Hematology–Oncology, University of Pennsylvania, Philadelphia, USA
- Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, USA
| |
Collapse
|
38
|
Dijkstra H, Albada A, Klöckner Cronauer C, Ausems MGEM, van Dulmen S. Nonverbal communication and conversational contribution in breast cancer genetic counseling: are counselors' nonverbal communication and conversational contribution associated with counselees' satisfaction, needs fulfillment and state anxiety in breast cancer genetic counseling? PATIENT EDUCATION AND COUNSELING 2013; 93:216-223. [PMID: 23786807 DOI: 10.1016/j.pec.2013.05.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Revised: 04/28/2013] [Accepted: 05/19/2013] [Indexed: 06/02/2023]
Abstract
OBJECTIVE The current study aimed to examine how counselors' nonverbal communication (i.e. nonverbal encouragements and counselee-directed eye gaze) and conversational contribution (i.e. verbal dominance and interactivity) during the final visit within breast cancer genetic counseling relate to counselee satisfaction, needs fulfillment and anxiety. METHODS Breast cancer counselees (N=85) completed questionnaires measuring satisfaction, needs fulfillment and anxiety after the final consultation and anxiety before the initial visit. Consultations were videotaped. Counselor nonverbal encouragements and counselee-directed eye gaze were coded. Verbal dominance and interactivity were measured using the Roter Interaction Analysis System (RIAS). RESULTS More counselor nonverbal encouragements and higher counselor verbal dominance were both significantly related to higher post-visit anxiety. Furthermore, counselor verbal dominance was associated with lower perceived needs fulfillment. No significant associations with eye gaze and interactivity were found. CONCLUSION More research is needed on the relationship between nonverbal encouragements and anxiety. Given the unfavorable association of counselor verbal dominance with anxiety and needs fulfillment, more effort could be devoted to involve counselees in the dialog and reduce the counselor's verbal contribution during the consultation. PRACTICE IMPLICATIONS Interventions focused on increasing counselees' contribution in the consultation may be beneficial to counselees.
Collapse
Affiliation(s)
- Henriëtta Dijkstra
- Netherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands
| | | | | | | | | |
Collapse
|
39
|
From constraints to opportunities? Provision of psychosocial support in portuguese oncogenetic counseling services. J Genet Couns 2013; 22:771-83. [PMID: 23990318 DOI: 10.1007/s10897-013-9612-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2011] [Accepted: 05/20/2013] [Indexed: 10/26/2022]
Abstract
Although available guidelines for familial cancer risk counseling clearly state the need to provide adequate psychosocial assessments and support, this feature of care is only available in part for individuals and families in oncogenetic counseling protocols in Portugal. The purpose of this study was to examine the psychosocial aspects of oncogenetic counseling provided by a sample of Portuguese genetics professionals. We sought to ascertain perceived need for the provision of psychosocial services and ways to enhance the psychosocial focus in service delivery. A qualitative study was designed; semi-structured focus groups and individual interviews were performed with 30 professionals from Portuguese healthcare institutions where oncogenetic counseling is offered. Findings suggest: current practice is aligned with the teaching model, with a mainly information-based focus; use of psychosocial counseling techniques and psychosocial support is limited throughout the genetic counseling timeline; there is a limited workforce of adequately trained psychosocial professionals, who are disadvantaged by structural and organizational constraints. These factors are considered to be serious barriers for psychosocial delivery. Development of multidisciplinary teams working in oncogenetics, and need for further counselling skills and training for genetics healthcare professionals were identified as priorities. Implications for practice and policy are discussed. Portuguese genetic counselors who have recently completed their training, may therefore contribute to enhanced psychosocial services delivery.
Collapse
|
40
|
Wiering BM, Albada A, Bensing JM, Ausems MGEM, van Dulmen AM. The influence of dispositional optimism on post-visit anxiety and risk perception accuracy among breast cancer genetic counselees. Psychooncology 2013; 22:2419-27. [PMID: 23630180 DOI: 10.1002/pon.3292] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2012] [Revised: 03/10/2013] [Accepted: 03/24/2013] [Indexed: 11/07/2022]
Abstract
OBJECTIVE Much is unknown about the influence of dispositional optimism and affective communication on genetic counselling outcomes. This study investigated the influence of counselees' optimism on the counselees' risk perception accuracy and anxiety, while taking into account the affective communication during the first consultation for breast cancer genetic counselling. METHODS Counselees completed questionnaires measuring optimism, anxiety and the perceived risk that hereditary breast cancer runs in the family before, and anxiety and perceived risk after the first consultation. Consultations were videotaped. The duration of eye contact was measured, and verbal communication was rated using the Roter Interaction Analysis System. RESULTS Less-optimistic counselees were more anxious post-visit (β = -.29; p = .00). Counsellors uttered fewer reassuring statements if counselees were more anxious (β = -.84; p = .00) but uttered more reassurance if counselees were less optimistic (β = -.76; p = .01). Counsellors expressed less empathy if counselees perceived their risk as high (β = -1.51; p = .04). An increase in the expression of reassurance was related to less post-visit anxiety (β = -.35; p = .03). More empathy was related to a greater overestimation of risk (β = .92; p = .01). CONCLUSIONS Identification of a lack of optimism as a risk factor for high anxiety levels enables the adaptation of affective communication to improve genetic counselling outcomes. Because reassurance was related to less anxiety, beneficial adaptation is attainable by increasing counsellors' reassurance, if possible. Because of a lack of optimally adapted communication in this study, further research is needed to clarify how to increase counsellors' ability to adapt to counselees.
Collapse
Affiliation(s)
- B M Wiering
- NIVEL (Netherlands Institute for Health Services Research), Utrecht, The Netherlands
| | | | | | | | | |
Collapse
|
41
|
Tercyak KP, O'Neill SC, Roter DL, McBride CM. Bridging the Communication Divide: A Role for Health Psychology in the Genomic Era. ACTA ACUST UNITED AC 2012; 43:568-575. [PMID: 23503693 DOI: 10.1037/a0028971] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The application of genomics to population health has the potential to revolutionize the practice of medicine. Indeed, discoveries into the genomic basis of cancer and other common chronic diseases have resulted in new and improved predictive tests for identifying individuals at increased risk for these conditions and long before their onset occurs. When used properly, information gained from predictive genomic tests can be combined with other leading indicators (e.g., environmental and behavioral risk factors) to inform medical management decisions, preventive health practices, and risk-reducing strategies. However, genomics remains an emerging science and the translation of genomic discoveries into improved population health management remains elusive. There are divides in the translational science continuum at several junctures, and many of these divides could be narrowed or closed with additional data. For example, we know relatively little about how to effectively communicate with the public about the complex interplay among genomics, behavior, and health. Moreover, there is a need to develop better methods of counseling and educating the public in light of newly emerging knowledge about the genomic basis of health and disease. We assert that the discipline of psychology, and health psychology in particular, is well-poised to continue to make significant contributions to this growing area of science and practice. Through a focus on health-related social and behavioral research, psychology can lead the way in overcoming divides in communication, understanding, and action about genomics for the betterment of both individual and public health practices.
Collapse
Affiliation(s)
- Kenneth P Tercyak
- Departments of Oncology and Pediatrics, Georgetown University School of Medicine, Washington, DC
| | | | | | | |
Collapse
|
42
|
Albada A, van Dulmen S, Lindhout D, Bensing JM, Ausems MGEM. A pre-visit tailored website enhances counselees' realistic expectations and knowledge and fulfils information needs for breast cancer genetic counselling. Fam Cancer 2012; 11:85-95. [PMID: 21901499 DOI: 10.1007/s10689-011-9479-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Counselees who are the first in their family to request breast cancer genetic counselling often don't know what to expect or have unrealistic expectations of genetic counselling. Receiving tailored information might help them to prepare for their first visit. We conducted a study of the effects of a pre-visit website providing computer-tailored information (E-info gene(ca)), on counselees' expectations, knowledge about breast cancer and heredity and information needs. Counselees were randomized to receive usual care (UC) or UC plus website. All counselees completed a baseline questionnaire and those randomized to the intervention group also completed a questionnaire after having viewed the website. After having accessed E-info gene(ca) counselees (n = 101) better knew what to expect of their first visit (χ(2) = 4.43; P = .04) and less often showed unrealistic expectations about possibilities for DNA-testing (χ(2) = 4.84; P = .03) than counselees in the UC group (n = 89). In addition, the website increased counselees' knowledge of breast cancer and heredity (B = .23; P = .003) and lowered their information needs (B = -.16; P = .000) compared to the UC group. Especially, information concerning procedural aspects and emotional consequences of genetic counselling was considered less important. This study showed that counselees know more and need less when they are provided with extended pre-visit information through a tailored website and counselees enter the visit with more realistic expectations of genetic counselling. This might facilitate and focus communication within the subsequent consultation.
Collapse
Affiliation(s)
- Akke Albada
- NIVEL (Netherlands Institute for Health Services Research), P.O. Box 1568, 3500 BN, Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
43
|
van Riel E, van Dulmen S, Ausems MGEM. Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral. J Community Genet 2012; 3:265-74. [PMID: 22426886 DOI: 10.1007/s12687-012-0090-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2011] [Accepted: 03/06/2012] [Indexed: 01/29/2023] Open
Abstract
Both physician and patient play a role in the referral process for cancer genetic counseling. Access to such counseling is not optimal because some eligible patients are not being reached by current referral practice. We aimed to identify factors associated with the initiator of referral. During a 7-month period, we recorded demographic characteristics like gender, personal and family history of cancer, ethnicity and eligibility for genetic testing for 406 consecutive counselees using a specially designed questionnaire. Counselees were seen in a university hospital or a community hospital (n = 7) in the Netherlands. We also recorded educational level of each counselee, clinical setting and who initiated referral. Descriptive statistics were used to describe the counselees' general characteristics. We analysed the association between counselee characteristics and the initiator of referral by logistic regression. The majority of counselees seemed to have initiated referral themselves but were indeed eligible for genetic testing. In comparison to the general population in the Netherlands, the counselees had a higher level of education, and there were fewer immigrants, although a higher level of education was not found to be a facilitating factor for referral. The clinical setting where a counselee was seen was associated with initiator of referral, although this relationship was not straightforward. There is a complex interaction between clinical setting and initiator of referral, which warrants further research to elucidate the factors involved in this relationship. Patients seen in cancer genetic counseling do not reflect the general population in terms of educational level or ethnicity.
Collapse
Affiliation(s)
- E van Riel
- Department of Medical Genetics, University Medical Centre Utrecht, P.O. Box 85090, 3508 AB, Utrecht, The Netherlands,
| | | | | |
Collapse
|
44
|
Albada A, van Dulmen S, Bensing JM, Ausems MGEM. Effects of a pre-visit educational website on information recall and needs fulfilment in breast cancer genetic counselling, a randomized controlled trial. Breast Cancer Res 2012; 14:R37. [PMID: 22394647 PMCID: PMC3446371 DOI: 10.1186/bcr3133] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2011] [Revised: 02/20/2012] [Accepted: 03/06/2012] [Indexed: 11/16/2022] Open
Abstract
Introduction Pre-visit education which helps counselees to prepare for their first visit for breast cancer genetic counseling might enhance information recall and needs fulfilment. This study assessed the effects of a pre-visit website with tailored information and question prompt sheet (QPS), named E-info geneca. Methods A total of 197 counselees were randomized to receive usual care (UC) or UC plus E-info geneca. All counselees completed a pre- and post-visit questionnaire and visits were videotaped. We studied effects on counselees' information recall, knowledge about breast cancer and heredity, fulfillment of needs, risk perception alignment, anxiety and perceived personal control, using multilevel regression analyses. Results Intent-to-treat analysis showed that counselees in the intervention group (n = 103) had higher levels of recall of information from the consultation (β = .32; confidence interval (CI): .04 to .60; P = .02; d = .17) and post-visit knowledge of breast cancer and heredity (β = .30; CI: .03 to .57; P = .03) than counselees in the UC group (n = 94). Also, intervention group counselees reported better fulfilment of information needs (β = .31; CI: .03 to .60; P = .03). The effects of the intervention were strongest for those counselees who did not receive an indication for DNA testing. Their recall scores showed a larger increase (β = .95; CI: .32 to 1.59; P = .003; d = .30) and their anxiety levels dropped more in the intervention compared to the UC group (β = -.60; CI: -1.12 to -.09; P = .02). No intervention effects were found after the first visit on risk perception alignment or perceived personal control. Conclusions This study shows that pre-counseling education, using tailored information technology, leads to more effective first visits for breast cancer genetic counseling, in particular for counselees who received no indication for DNA testing and, therefore, had no indication for a second visit. Future study should focus on the effects of a pre-visit website on the outcomes after a complete series of visits. Trial registration Dutch Trial Register ISRCTN82643064.
Collapse
Affiliation(s)
- Akke Albada
- NIVEL (Netherlands Institute for Health Services Research), Otterstraat 118-124, Utrecht, 3500 BN, the Netherlands.
| | | | | | | |
Collapse
|
45
|
Brédart A, Kop JL, Fall M, Pelissier S, Simondi C, Dolbeault S, Livartowski A, Tardivon A. Perception of care and experience of examination in women at risk of breast cancer undergoing intensive surveillance by standard imaging with or without MRI. PATIENT EDUCATION AND COUNSELING 2012; 86:405-413. [PMID: 21795009 DOI: 10.1016/j.pec.2011.06.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Revised: 05/11/2011] [Accepted: 06/28/2011] [Indexed: 05/31/2023]
Abstract
OBJECTIVE Intensive surveillance in women at breast cancer risk is currently investigated in a French prospective, non-randomized, multicenter study, in which standard imaging--mammography±ultrasound ('Mx') and standard imaging combined with magnetic resonance imaging ('MRI') are compared with regard to perception of care and examination experience. METHODS 1561 women were invited to complete the STAI-State Anxiety Inventory and breast cancer risk perception items at baseline (T0), and MGQ (MammoGraphy Questionnaire) and MRI discomfort items within 2 days after examinations (T1). RESULTS Baseline compliance was high (>91%). Women from the 'MRI' group were significantly younger and displayed higher education level and risk perception. MRI discomfort related to the duration, immobility, prone position or noise was experienced by more than 20% of women. In multivariate analyses, 'MRI' was associated with more favorable examination psychological experience (p≤.001), especially in women younger than 50; baseline STAI-State anxiety was associated with lower MGQ scores (p≤.001) and higher MRI discomfort (p≤.001). CONCLUSION In spite of the discomfort experienced with MRI, perception of care and experience with this surveillance procedure was more positive than with standard imaging. PRACTICE IMPLICATIONS Information and support may assuage some of the adverse effects of an uncomfortable examination technique.
Collapse
Affiliation(s)
- Anne Brédart
- Psycho-Oncology Unit, Supportive Care Department, Institut Curie, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2011; 21:151-61. [PMID: 22134580 DOI: 10.1007/s10897-011-9462-x] [Citation(s) in RCA: 235] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2011] [Accepted: 11/16/2011] [Indexed: 12/28/2022]
Abstract
Updated from their original publication in 2004, these cancer genetic counseling recommendations describe the medical, psychosocial, and ethical ramifications of counseling at-risk individuals through genetic cancer risk assessment with or without genetic testing. They were developed by members of the Practice Issues Subcommittee of the National Society of Genetic Counselors Familial Cancer Risk Counseling Special Interest Group. The information contained in this document is derived from extensive review of the current literature on cancer genetic risk assessment and counseling as well as the personal expertise of genetic counselors specializing in cancer genetics. The recommendations are intended to provide information about the process of genetic counseling and risk assessment for hereditary cancer disorders rather than specific information about individual syndromes. Essential components include the intake, cancer risk assessment, genetic testing for an inherited cancer syndrome, informed consent, disclosure of genetic test results, and psychosocial assessment. These recommendations should not be construed as dictating an exclusive course of management, nor does use of such recommendations guarantee a particular outcome. These recommendations do not displace a health care provider's professional judgment based on the clinical circumstances of a client.
Collapse
|
47
|
Pieterse AH, Ausems MGEM, Spreeuwenberg P, van Dulmen S. Longer-term influence of breast cancer genetic counseling on cognitions and distress: smaller benefits for affected versus unaffected women. PATIENT EDUCATION AND COUNSELING 2011; 85:425-431. [PMID: 21316181 DOI: 10.1016/j.pec.2011.01.017] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2010] [Revised: 12/23/2010] [Accepted: 01/11/2011] [Indexed: 05/30/2023]
Abstract
OBJECTIVE To evaluate outcomes of breast cancer genetic counseling in women with and without breast cancer. METHODS Seventy-seven first-time attendees (n=44 affected) completed questionnaires assessing cognitions (risk accuracy, knowledge, perceived personal control [PPC]) and distress (state anxiety [STAI], cancer-related stress reactions [IES]) from immediately before to immediately and six months after completing counseling. Data were analyzed using multilevel repeated measures and trend analyses. RESULTS In affected counselees, mean cognitions did not significantly differ over time, anxiety significantly decreased, and IES levels were increased immediately post-counseling. In unaffected counselees, cognitions significantly improved over time except for knowledge. Distress levels showed similar patterns as in affected women. Improvements in cognitions and distress were significantly smaller in affected versus unaffected women. CONCLUSION Overall, counseling educates women about breast cancer risk and alleviates their anxiety. Importantly, benefits gained at immediate follow-up seem maintained over time. PRACTICE IMPLICATION Affected women seem to benefit less from counseling. Counselors may need to devote more effort into educating these women and addressing their anxieties. Future studies should confirm the unexpected finding that cancer-related distress increased immediately post-counseling.
Collapse
Affiliation(s)
- Arwen H Pieterse
- Department of Medical Decision Making, Leiden University Medical Centre, Leiden, The Netherlands.
| | | | | | | |
Collapse
|
48
|
Albada A, Ausems MGEM, Otten R, Bensing JM, van Dulmen S. Use and evaluation of an individually tailored website for counselees prior to breast cancer genetic counseling. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2011; 26:670-681. [PMID: 21533850 DOI: 10.1007/s13187-011-0227-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
This article explores the use and evaluation of a pre-visit website which aims to prepare counselees who are the first in their family to request breast cancer genetic counseling. This website E-info gene(ca) provides computer-tailored information and a blank question prompt sheet (QPS) on which counselees can formulate their questions for the consultation. The objectives of this study are: first, to assess which factors influence the use of E-info gene(ca), including the duration of site and page views, the influence of topic sequence in the menu bar on the sequence of page views, and the relation between website use and the use of the QPS; second, to explore counselees' evaluations of E-info gene(ca) and relations with counselee characteristics. User statistics were analyzed to describe duration of site and page views. Multivariate analyses were used to predict duration of web and page views, sequence of page views, QPS use, and site evaluations. Independent variables were sociodemographic background, disease status, psychological functioning, and information needs. All 101 counselees who were provided with a login accessed the website and spent, on average, 21 min viewing the website. Counselees affected with breast cancer spent more time on the website than unaffected counselees. Half of all page views were within the sequence of topics in the menu and older counselees, and those who made less use of the internet more often navigated according to the menu sequence than others. Having viewed information about why it is important to ask questions increased QPS use. Counselees who had higher information needs considered the information more helpful. This hospital-provided website for breast cancer genetic counselees was accessible and was evaluated positively, even concerning older counselees and those who had not searched the internet for information about hereditary cancer. Counselees might navigate hospital-provided websites more in line with the sequence of topics in the menu bar, than generally accessible health websites.
Collapse
Affiliation(s)
- Akke Albada
- NIVEL (Netherlands Institute for Health Services Research), P.O. Box 1568, 3500, BN, Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
49
|
Paneque M, Sequeiros J, Skirton H. Quality assessment of genetic counseling process in the context of presymptomatic testing for late-onset disorders: a thematic analysis of three review articles. Genet Test Mol Biomarkers 2011; 16:36-45. [PMID: 21819246 DOI: 10.1089/gtmb.2011.0023] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Presymptomatic testing (PST) is available for a range of late-onset disorders. Health practitioners generally follow guidelines regarding appropriate number of counseling sessions, involvement of multidisciplinary teams, topics for pretest discussion, and follow-up sessions; however, more understanding is needed about what helps consultands effectively and the impact of amount and quality of genetic counseling on the psychosocial sequelae of PST for late-onset disorders. We conducted a thematic analysis of three review articles on quality of the genetic counseling process, aiming at (1) exploring current evidence; (2) identifying quality assessment indicators; and (3) making recommendations for genetic counseling practice in late-onset disorders. We undertook a systematic search of 6 relevant databases: 38 articles were identified and 3 fitted our inclusion criteria; after quality appraisal, all were included in the review. The number of sessions, time spent, consultation environment, follow-up, and multidisciplinarity were identified as variables for quality assessment. Research on counseling in the context of genetic testing in familial cancer tends to be related to outcomes and indicators for quality assessment, while research concerning other late-onset diseases is mainly focused on the psychological impact of the test results. The quality and content of the overall process in noncancer late-onset diseases is insufficiently articulated. Despite the fact that PST for Huntington disease and other degenerative conditions has been offered for more than 20 years, good methodological approaches to assess quality of genetic counseling in that context remain elusive. This restricts improvement of the protocols for genetic services and, in general, healthcare for the at-risk population.
Collapse
Affiliation(s)
- Milena Paneque
- Center for Predictive and Preventive Genetics-CGPP, Institute for Molecular and Cell Biology-IBMC, ICBAS, University of Porto, Porto, Portugal.
| | | | | |
Collapse
|
50
|
Tluczek A, Zaleski C, Stachiw-Hietpas D, Modaff P, Adamski CR, Nelson MR, Reiser CA, Ghate S, Josephson KD. A tailored approach to family-centered genetic counseling for cystic fibrosis newborn screening: the Wisconsin model. J Genet Couns 2010; 20:115-28. [PMID: 20936425 DOI: 10.1007/s10897-010-9332-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2010] [Accepted: 09/15/2010] [Indexed: 12/30/2022]
Abstract
This article describes the development of a tailored family-centered approach to genetic counseling following abnormal newborn screening (NBS) for cystic fibrosis (CF). A genetic counseling consortium reviewed research literature, selected theoretical frameworks, and incorporated counseling psychology micro skills. This innovative intervention integrated theories and empirically validated techniques. Pilot testing and parent feedback confirmed satisfaction with and feasibility of the approach designed to (a) minimize parents' distress, (b) facilitate parents' understanding, (c) increase parents' capacities to use genetic information, and (d) enhance parents' experiences with genetic counseling. Counselors engage in a highly interactive process of evaluating parents' needs and tailoring assessments and interventions that include a therapeutic environment, the family's emotional needs, parents' informational needs, and a follow-up plan. This promising new model is the first to establish a theory-driven, evidence-based standard for genetic counseling in the context of NBS for CF. Additional research will evaluate the model's efficacy in clinical practice.
Collapse
Affiliation(s)
- Audrey Tluczek
- University of Wisconsin, School of Nursing, 600 Highland Ave. K6/346, Madison, WI 53792, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|